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1. INTRODUCTION 
 
 
The mammalian immune system is composed of many cell types and mediators that 
interact with non-immune cells and each other in complex and dynamic networks to 
ensure protection against foreign pathogens, while simultaneously maintaining 
tolerance towards self-antigens. 
Based on antigen specificity and timing of activation, the immune system is 
composed of two distinct compartments — adaptive and innate. 
  
Innate immune cells including dendritic cells (DCs), macrophages, neutrophils, 
basophils, eosinophils, natural killer (NK) and mast cells are the first line of defence 
against foreign pathogens.  
The unique characteristic of innate immune cells — their inherent ability to rapidly 
respond when tissue injury occurs, without memory of previous assaults or antigen 
specificity — is a defining feature that sets them apart from adaptive immune cells.  
Adaptive immune cells, B and T lymphocytes, produced by stem cells in the bone 
marrow, mature in the thymus and/or lymph nodes and ensure that most mammals 
that survive an initial infection by a pathogen are generally immune to further illness 
caused by that same pathogen. 
 
 
1.1 INFLAMMATORY MEDIATORS: CYTOKINES AND CHEMOKINES  
Reciprocal interactions that exist between the innate and adaptive cells and non-
immune cells (such as stroma and endothelial cells, tumor cells) are mediated by 
inflammatory cytokines and chemokines, which may affect inflammatory responses 
and tumor development and progression. 
 
Cytokines are produced by all cells of the innate and adaptive immune systems and 
some of non immune cells. Interleukins are cytokines that act as communication 
mediators between different leukocytes to facilitate regulation of these immune cells. 
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As promoter of cell growth and division, a cytokine acts as a messenger to cells, and 
the transmission of the message requires a binding of the cytokine molecule to a 
cytokine-specific receptor on the cell surface. 
 
Each cytokine regulates the intensity and type of inflammatory and immune response 
that is triggered. The effect of a mixture of various cytokine exposures on a specific 
target cell may be synergistic or antagonistic in the ultimate immune activity effect. 
 
Chemokines are a subclass of cytokines that direct the migration of leukocytes to 
sites of inflammation. Recently, it has been observed that tumors express chemokine 
receptors (Scotton C.J., et al., 2001; Wang J.M., et al., 1998; Azenshtein E., et al., 
2002). Thus, it should not come as a surprise that, aside from their role in mediating 
the recruitment of tumor-infiltrating leukocytes to tumor sites, chemokines may also 
affect neoplastic proliferation, neovascularization and metastasis. 
 
Through the interaction with their receptors, the chemokines induce cytoskeletal 
rearrangement, firm adhesion to endothelial cells, and directional migration. 
Chemokines act in a coordinated fashion with cell surface proteins, including 
integrins, to direct the specific homing of various subsets of haematopoietic cells to 
specific anatomical sites. 
 
 
1.2 ACUTE INFLAMMATION AND TISSUE HOMEOSTASIS 
 
1.2.1 Innate immune response 
Cells damaged by a myriad of events, such as mechanical, physical, chemical, or 
biologic injury, activate pathways that initiate the process known as acute phase of 
the inflammatory response. 
 
The first responders to cell damage are the phagocytic cells of the innate immune 
system that are activated by complex signals as they rapidly accumulate in the 
damaged tissue. 
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Polymorphonuclear leukocytes are the first phagocytic cells arriving from the 
intravascular compartment to the site of injury or damage and accumulate within 30 
to 60 min of damage. 
In the inflammatory response signals persist beyond 50 to 60 hr, the site of injury is 
infiltrated by macrophages and lymphocytes, phagocytic cells that are widely 
distributed throughout the body and are housed in local tissue.  
 
In addition to phagocytic activities, the macrophages become activated prompting 
their release of acute-phase proteins known as cytokines and chemokines, or 
signalling proteins. These signalling proteins potentiate the inflammatory response 
and induce mobilization and infiltration of additional leukocytes into damaged tissue. 
 
The activation and directed migration of leukocytes into the inflamed tissue are 
coordinated by a four-step mechanism. These steps involve: activation of members 
of the selectin family of adhesion molecules (L, P and E-selectin) that facilitate rolling 
along the vascular endothelium; triggering of signals that activate and up regulate 
leukocyte integrins mediated by cytokines and leukocyte-activating molecules; 
immobilization of neutrophils on the surface of the vascular endothelium by binding to 
endothelial vascular cell-adhesion molecule-1 (VCAM-1, ICAM-1); transmigration 
through the endothelium to sites of injury, presumably facilitated by extracellular 
proteases, such as matrix metalloproteinases (MMPs). 
Receptor upregulation increases extravasation of neutrophils, monocytes, activated 
T-helper and T-cytotoxic, and memory T and B cells to the infected site. 
 
Macrophages and mast cells can also activate vascular and fibroblast responses in 
order to orchestrate the elimination of invading organisms and initiate local tissue 
repair. DCs, on the other hand, take up foreign antigens and migrate to lymphoid 
organs where they present their antigens to adaptive immune cells. They are, 
therefore, key players in the interface between innate and adaptive immunity. NK 
cells also participate in cellular crosstalk between innate and adaptive immune cells 
through their ability to interact bidirectionally with DCs; certain NK-cell subsets 
eliminate immature DCs, whereas others promote DC maturation, which can then 
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also reciprocally regulate activation of NK cells (Hamerman J.A., et al., 2005; Degli 
Esposti M.A., Smyth M.J., 2005; Raulet D.H., 2004).  
 
1.2.2 Adaptive immune response 
Acute activation of innate immunity sets the stage for activation of the more 
sophisticated adaptive immune system.  
Induction of efficient primary adaptive immune responses requires direct interactions 
with mature antigen-presenting cells and a proinflammatory milieu. 
 
Adaptive immune cells, including B lymphocytes, CD4+ helper and CD8+ cytotoxic T 
lymphocytes (CTLs), distinguish themselves from innate leukocytes by expression of 
somatically generated, diverse antigen-specific receptors, which are formed as a 
consequence of random gene rearrangements and allow a flexible and broader 
repertoire of responses than innate immune cells, which express germline-encoded 
receptors. As individual B and T lymphocytes are antigenically committed to a 
specific unique antigen, clonal expansion upon recognition of foreign antigens is 
required to obtain sufficient antigen-specific B and/or T lymphocytes to counteract 
infection.  
 
Therefore, the kinetics of primary adaptive responses is slower than innate 
responses. However, during primary responses a subset of lymphocytes differentiate 
into long-lived memory cells, resulting in larger responses upon subsequent 
exposure to the same antigen. 
Together, acute activation of these distinct immune-response pathways efficiently 
removes or eliminates invading pathogens, damaged cells and extracellular matrix 
(ECM). In addition, once assaulting agents are eliminated, immune cells are crucially 
involved in normalizing cell-proliferation and cell-death pathways to enable re-
epithelialization and new ECM synthesis. Once wound healing is complete, 
inflammation resolves and tissue homeostasis returns. 
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1.3 CHRONIC INFLAMMATION AND CANCER DEVELOPMENT  
In a homeostatic context, when tissues are wounded or exposed to a chemical 
irritant, inflammatory cells are involved in removing damaged cells by induction of cell 
death and phagocytic pathways, as well as in enhancing matrix metabolism and cell 
proliferation to facilitate tissue regeneration or wound healing. Proliferation and 
inflammation subside after the assaulting agent is removed or the repair completed. 
 
When tissue homeostasis is chronically perturbed, interactions between innate and 
adaptive immune cells can be disturbed.  
 
Both acute and chronic inflammatory disorders are initiated by the same intrinsic 
molecular and cellular inflammatory responses despite the different duration of the 
presence of inflammation. (Gabay C. and Kushner I., 1999). 
 
Lymphocytes, plasma cells, monocytes, macrophages, fibroblasts and endothelial 
cells represent the cellular components of the chronic inflammatory process. 
Just as neutrophils are the primary effectors cells in acute inflammation, 
macrophages play a prominent role in chronic inflammation. In the injured tissue, 
macrophages extravasate via the same methods discussed above (ICAM-1 VCAM-
1). These cells are powerful defensive agents of the body, but the toxins they release 
(including reactive oxygen species) are injurious to the organism's own tissues as 
well as invading agents. This is why chronic inflammation is almost always 
accompanied by tissue destruction.  
 
Many evidences support that individuals suffering from chronic inflammatory 
disorders harbour a greatly increased risk of cancer development (Coussens L., 
Werb Z., 2002; Balkwill F., et al., 2005), largely due to the pro-growth environment 
generated by activated inflammatory cells. 
 
Sustained proliferation of “initiated/mutant” cells in environments rich in inflammatory 
cells, growth/survival factors, activated stroma, and DNA damage promoting agents, 
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potentiates and/or “promotes” neoplastic risk (Coussens L., Werb Z., 2002; Thun 
M.J., et al., 2004; Clevers H., et al., 2004; Shacter E., et al., 2002). 
 
Cancer development is a multi-step process, during which genetic alterations 
(mutations that produce oncogenes with dominant gain of function and tumor 
suppressor genes with recessive loss of function) confer specific types of growth 
advantage. Malignant growth is characterized by several key changes: self-
sufficiency of growth signals, insensitivity to antigrowth signals, escaping from 
apoptosis, unregulated proliferation potential, enhanced angiogenesis, and 
metastasis (Hanahan D., Weinberg R.A., 2000). 
 
Metastasis represents a highly organized, non-random, and organ-selective process 
and it is the result of several sequential steps (Nicolson G.L., 1993). These include 
growth; neovascularization and lymphangiogenesis (development of new lymphatic 
vessels); invasion of the host stroma, blood vessels, and lymphatic system; survival 
in the circulation; arrest in small blood vessels; extravasation (migration out of blood 
vessels) into the parenchyma of organs; and continuous proliferation, which depends 
on establishing an adequate blood supply (angiogenesis) (Any macroscopic new 
tissue, whether resulting from repairing a wound, normal growth, or tumors, requires 
a blood supply, with blood vessel growth in tumors initiated by chemical triggers 
called "tumor angiogenesis factors"). 
In all stages of metastasis, malignant cells must resist to antitumor defences of the 
body in order to survive (Mehlen P., Puisieux A., 2006). 
 
The tumor microenvironment is composed not only of resident tissue cells, such as 
fibroblasts, epithelial cells and cells that form blood and lymphatic vasculature, but 
also of inflammatory cells that have infiltrated the tumor.  
Inflammatory cell infiltrates in pre-malignant tissues and tumours can be differentially 
composed of diverse leukocytic populations, adaptive and/or innate, depending upon 
the stage of tumour development and the organ micro-environment. 
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Innate immune cells, e.g., granulocytes (neutrophils, basophils and eosinophils), 
dendritic cells (DCs), macrophages, natural killer cells (NK cells) and mast cells, are 
prominent components of pre-malignant and malignant tissues (Coussens L., Werb 
Z., 2002; de Visser KE, et al., 2006). 
 
If inflammatory conditions prevail at the tumor site, they may further support the 
progression of the tumor into more advanced stages and also promote metastasis. 
 
 
1.4 IMMUNOSURVEILLANCE AND IMMUNOSTIMULATION  
Based on the observation that a tumor is in a state of chronic inflammation, Dvorak 
compared cancer to a wound that never heals (Dvorak H.F., 1986). Numerous tumor 
types constitutively produce cytokines and chemokines; this results in the migration 
of immune cells into tumors which have different roles in cancer development. 
 
Two distinct theories aim to define the role of the immune system in cancer. The 
theory of immunosurveillance postulates that the role of the immune response in 
cancer is one of protection; in contrast, the theory of immunostimulation postulates 
that the role of the immune response in spontaneous neoplasia is not one of 
protection, but rather of tumor promotion. 
 
To explain the conflicting roles of the immune response in neoplasia it must be noted 
that the immune system is not a single entity, but a complex system of constituents 
which active distinct immunological pathways.  
 
1.4.1 The theory of immunosurveillance 
The theory of immunosurveillance postulates that constituents of the immune system 
such as natural killer (NK) cells and cytokine networks may be able to protect against 
cancer.  
 
NK are involved, directly or indirectly, in the surveillance of incipient tumors and 
micro-metastasis. 
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It is likely that the role of NK cells is to activate other cells of the immune system 
through providing cytokine support (Miller J.S., 2001). Mature NK cells do not 
produce T-helper 2 (Th2) cytokines, but rather the T-helper 1 (Th1) cytokines, tumor 
necrosis factor (TNF)-α, interferon (IFN)-γ  and GM-CSF (Loza M.J., Perussia B., 
2001). 
 
The Th-1 cytokine IFN-γ has both direct and indirect anti-tumor properties. IFN-γ  has 
been shown to have a direct anti-proliferative, pro-apoptotic and anti-angiogenic 
effects on certain tumor models (Kominsky S., et al., 1998; Hobeika A.C., et al., 
1999; Kominsky S.L., et al., 2000).  
 
Moreover, IFN-γ has indirect antitumor effects. In addition to influencing the Th1-Th2 
cytokine balance, IFN-γ  can activates cytotoxic macrophages, NK cells and NK T 
cells (Ikeda H., et al., 2002). 
 
1.4.2 The theory of immunostimulation 
The theory of immunostimulation postulates that an inappropriate type of immune 
response will enhance tumor growth. 
Several physiological processes that are necessary for tumor development, such as 
increased cell survival, tissue remodelling, angiogenesis and suppression of 
antitumor adaptive immune response, are often regulated by leukocytic infiltrates in 
neoplastic environments. 
In addition, these cells may to favour the generation of a non-protective Th2 immune 
response.  
 
In general, Th2-driven antibody responses to tumors are non-protective and may 
contribute to tumor progression by inhibiting the Th1 cell-mediated immune response 
(Clerici M., et al., 1996). 
It was theorized that the antibody bind to tumor cells, masking their epitopes and thus 
preventing a cell-mediated immune response, although this has never been 
demonstrated experimentally. 
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Innate immunity and cancer 
Mast cells and macrophages are examples of inflammatory cells that are often 
recruited to tumor sites through chemotactic gradients. 
 
The presence of mast cells in tumors facilitates tumor progression; mast cells secrete 
a number of growth factor that regulate angiogenesis and endothelial-cell survival, 
including TNF-α , IL-8, bFGF and VEGF and a number of cytokines that induce the 
chemotactic migration of macrophages into the tumor, including IL-1, IL-6, TNF-α , 
IL-8. 
 
Tumor-associated macrophages (TAMs) are derived from monocytes that are 
recruited largely by monocyte chemotactic protein (MCP) chemokines. 
 
TAMs have a dual role in neoplasms: although they may kill neoplastic cells following 
activation by IL-2, interferon and IL-12 (Brigati C., et al., 2002; Tsung K., et al., 2002), 
TAMs for the most part, produce a number of potent angiogenic and 
lymphangiogenic growth factors, cytokines and proteases, all of which are mediators 
that potentiate neoplastic progression, in particular IL-6, IL1β and TNF-α 
(Schoppmann S., et al., 2002).  
Chronically activated innate immune cells can also indirectly contribute to cancer 
development through suppression of antitumor adaptive immune responses, allowing 
tumor escape from immune surveillance. 
Suppressive macrophages produce copious amounts of IL-10 but low amounts of IL-
12 (Sica A., et al., 2000). This shift in the cytokine profile reinforces the Th2 
imbalance that is often present in cancer models.  
 
Adaptive immunity and cancer 
Adaptive immunity has a crucial role in regulating and activating innate immune cells 
in affected tissues. In particular, B lymphocytes and factors that are present in serum 
are essential for establishing chronic inflammatory states that are associated with 
neoplastic progression. Antibodies that are deposited into tissues can trigger 
activation of innate immune cells and maintain chronic inflammation by the cross-
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linking of Fc receptors or the activation of complement cascade (Hoebe K., et al., 
2004). 
To explain the conflicting roles of the immune response in neoplasia it must be noted 
that the immune system is not a single entity, but a complex system of constituents.  
The resolution of a pathogenic challenge requires not only the presence or absence 
of an immune reaction, but also the initiation of the proper type of immune reaction. It 
is only an immune response of the proper type and magnitude that will result in 
protection. An immune response against an agent that is not of the proper type and 
magnitude will be deleterious to the host. 
 
 
 
 
 
 
Fig.1 A model of innate and adaptive immune-cell functions during inflammation-
associated cancer development (De Visser K.E., et al. Nature, 2006). 
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1.5 ANTI-CANCER STRATEGIES  
The term immunotherapy refers to any approach that seeks to mobilize or manipulate 
the immune system of a patient for therapeutic benefit. In this regard, there are 
numerous strategies for improving the resistance of a patient to cancer that can 
either bolster antitumor adaptive immunity or neutralize cancer-promoting properties 
of innate immune cells. 
 
The identification of defined tumor antigens in human prompted the development of 
adoptive T-cell therapy. Yet, the most attractive strategy is vaccination, which is 
expected to induce both therapeutic T-cell immunity (in the form of tumour-specific 
effectors T cells) and protective T-cell immunity (in the form of tumour-specific 
memory T cells that can control tumour relapse). 
Efficient antigen presentation and T-cell priming are essential components of 
effective antitumor immunity and the dendritic cells are critical to both of these 
functions. 
The approaches for the therapeutic vaccination of individuals who have cancer rely 
on random encounter of the vaccine with host DCs. 
A lack of encounter of the vaccine antigen with DCs might result in the absence of an 
immune response. Alternatively, an inappropriate encounter, for example with 
inactivated DCs or with the wrong subset of DCs, might lead to silencing of the 
immune response. 
We do not know how tumour antigens need to be delivered to DCs in vivo to elicit an 
appropriate immune response (Merad M., et al., 2002; Banchereau J., 2005). 
 
Dendritic cells (DCs) are the professional antigen-presenting cells of the immune 
system. Immature DCs are present in peripheral tissues, where they possess the 
capacity to take up and process antigen into small peptides; in absence of 
inflammation, DCs remain in an immature state, and antigens are presented to T 
cells in the lymph node without co-stimulation, leading to either the deletion of T cells 
or the generation of inducible regulatory T cells. 
Tissue inflammation induces the maturation of DCs and their migration to draining 
lymph nodes for presentation to resting lymphocytes. The mature DCs express high 
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levels of cell-surface major histocompatibility complex (MHC) antigen complexes and 
co-stimulatory molecules. This allows the priming of CD4+ T helper cells and CD8+ 
cytotoxic T lymphocytes (CTLs), the activation of B cells and the initiation of an 
adaptive immune response.  
It is now known that activated CD4+ T-helper cells up regulate CD40 ligand, and that 
signalling through the CD40 receptor fully activates DCs. 
 
DCs participate to the regulation of the inflammatory reaction through the release of 
cytokines and chemokines (Banchereau J. et al., 1998). 
 
Therefore DCs-based vaccines are now being explored in the clinic. So far, most 
DCs vaccines have been used to stimulate immune response, in particular those for 
combating cancer. Recent findings indicate that whereas mature DCs induce 
immunity, immature or semi-mature DCs can cause immunological tolerance, 
opening up application in transplantation and autoimmunity (Figdor C.G., et al., 
2004).  
In every case, effective migration of DCs to secondary lymphoid organs is essential 
for the DCs to exert their immune regulatory effect. 
 
1.5.1 DCs-based vaccines 
Multiple factors contribute to the failure of DCs to prime effective antitumor response 
in tumor-bearing hosts: the low number of DCs available in the tumor site, poor 
access of DCs to tumor Ag, the limited capacity of tumor cells to activate intra-
tumoral DCs, and secretion by the tumor cells of factors that inhibit DCs maturation.  
Administration of DCs generated and loaded with tumor antigens ex vivo, can be 
used to circumvent tumor immunotolerance and thus as therapeutic cancer vaccines 
(Fong L., et al., 2000). 
A variety of preparations of DCs can stimulate antitumor immunity, including DCs 
loaded with proteins, DCs fused with tumor cells, and DCs transduced with tumor-
derived RNA or viral vectors. At present, all of these approaches rely on ex vivo 
manipulation of isolated DCs to produce the vaccine. 
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DCs vaccination has been facilitated by the development of methods to generate 
DCs from either rare, but proliferating, CD34+ precursors or from common, but 
mostly non-proliferating, CD14+ monocytes (so-called monocyte-derived DCs) 
(Banchereau J., et al., 2001). 
Although early clinical trials have indicated that DCs vaccines can induce anti-tumor 
immune responses in some cancer patients, much has still to be learned regarding 
the subtype, maturation and activation status of DCs, antigen loading, route of 
administration, the dose and timing interval, and migration of DCs-based vaccines. 
 
DCs migration  
The migration to secondary lymphoid organs is essential for the DCs to exert their 
immune regulatory effect. 
DCs migration is a complex process that involves a coordinate activation of different 
classes of effectors molecules: chemokines, adhesion molecules, as well as matrix 
metalloproteinase’s (MMPs) and lipid mediators.  
DCs maturation results in the down regulation of chemokine receptors associated 
with tissue retention, whereas CCR7 and CD62L are up regulated (Dieu M.C. et al., 
1998).  
The expression of CCR7 on mature DCs and on naïve and central memory T cells is 
essential for their coordinate migration to the T-cell area of draining lymph nodes 
because this migration is guided by CCL19 and CCL21, the two ligands for CCR7. 
Both chemokines are expressed by stromal cells in the T-cell area of secondary 
lymphoid organs (Scandella E. et al., 2004).  
Recently, was observed that the maturation-induced up-regulation of CCR7 
expression on human monocyte-derived DCs was insufficient to allow MoDCs 
migration to CCL19 and CCL21 (Scandella E. et al., 2002; Luft T. et al., 2002). 
Human MoDCs matured either with soluble CD40L or with Poly I:C markedly 
enhanced surface expression of CCR7 but was not at all or was only poorly 
responsive to CCL19 and CCL21. Interestingly, MoDCs migration to CCL19 and 
CCL21 was readily observed on maturation in the presence of the inflammatory 
mediator prostaglandin E2 (PGE2), though PGE2 did not change the expression level 
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of CCR7 on mature MoDCs, providing evidence for an alternative effect of PGE2 
(Scandella E. et al., 2004). 
 
DCs maturation 
The majority of clinical studies with DCs have been carried out using ex vivo 
generated monocyte-derived DCs by culturing monocytes with GM-CSF and IL-4. 
This simple procedure yields a homogeneous population of DCs that resemble 
interstitial DCs. These DCs are immature and require exogenous factors for 
maturation. 
It is not clear which maturation stimulus is best for the induction of tumor-specific T 
cells in vivo; however, MCM (monocyte-conditioned medium) mimic (IL-1β, TNF-α, 
IL-6 and PGE2) currently represents the cocktail more used in clinical trials. 
 
Pro- and anti-angiogenic molecules can emanate from cancer cells, endothelial cells, 
stromal cells, blood and the extracellular matrix. Their relative contribution is likely to 
change with type, site and tumor growth. 
The balance between pro- and anti-inflammatory signals present in 
microenvironments determines the phenotype and the behaviour of the immune cells 
at the site of inflammation. While DCs activated by proinflammatory signals (e.g. LPS 
and TNF-α) are characterized by pro inflammatory functions, exposure of DCs to 
antinflammatory molecules such as IL-10, IL-4 and PGE2 induces alternative program 
of activation characterized by peculiar membrane phenotype and function. 
  
At the same manner, is the balance between pro- and anti-inflammatory molecules of 
the maturation cocktail to determine the angiogenic and migratory programs in 
activated MoDCs and the release of important cytokines subset that regulate the 
nature and the efficacy of immune responses. In particular, the cytokines IL-12 and 
IL-23 produced by activated DCs work by distinct immunological pathways to 
regulate cellular immune responses critical for host defence and tumor suppression. 
 
IL-12 and IL-23: master regulators of innate and adaptive immunity 
IL-12 and IL-23 are critical cytokines that bridge innate and adaptive immunity. 
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IL-12 was originally discovered because of its ability to induce interferon-γ (IFN-γ) 
production, cell proliferation, and cytotoxicity mediated by natural killer cells and T 
cells (Snijders A., et al., 1996). It is now well established that IL-12 also plays a key 
role in the development of Th1 responses, leading to IFN-γ and IL-2 production 
(Trinchieri G., et al., 1994; Hayes M.P., et al, 1995).  
 
Interleukin-12 (IL-12) is a heterodimeric 70-kD (p70) cytokine composed of two 
covalently linked glycosylated, 40-kD (p40) and 35-kD (p35) chains (Gubler U., et al., 
1991). Although p35 is expressed in numerous cell types, p40 expression is more 
restricted and determines the ability of a given cell-type to produce bioactive IL-12 
(Gately M.K., et al., 1998). However, in the cells that are capable of producing both 
IL-12 subunits, it is the p35 subunit, produced in much lower amounts than p40 that 
plays the role of a limiting factor and determines the amount of bioactive IL-12p70 
that is secreted (Snijders A., et al., 1996). 
 
IL-12 is mainly produced by monocytes, macrophages, and dendritic cells in 
response to bacterial products such as lipopolysaccharides (LPS), to intracellular 
pathogens (D’Andrea A., et al., 1992; Trinchieri G., et al., 1994) or during their 
interaction with Th cells, as a result of CD40-CD40L interaction between these 2 cell 
types (Kelsall B.L. et al., 1996). 
Several studies have suggested that only p40 is highly regulated by LPS, whereas 
p35 is constitutively expressed at low levels in peripheral blood mononuclear cells 
(D’Andrea A., et al., 1992). Therefore, depending on the cell type and the kind of 
stimuli, p35 and p40 mRNA expression may be regulated differently.  
P40 homodimer and p40 monomer secreted by antigen presenting cells (APCs) in 
absence of p35 production act as antagonists of mouse and human IL-12 receptors, 
inhibiting IL-12-dependent immune functions both in vitro and in vivo (Gately M.K., et 
al., 1998; Mattner F. et al., 1993; Mazzeo D., et al., 1998).  
 
IL-23 can be produced by inflammatory macrophages and activated DCs; formation 
of biologically active IL-23 required synthesis of both p19 and p40 subunits within the 
same cell (Oppmann B., et al., 2000). 
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 Whereas IL-12 leads to development of “classical” interferon-γ-producing Th1 cells 
and enhances cytotoxic, antimicrobial and anti-tumor responses, IL-23 drives a 
pathway that leads to the generation of IL-17-producing CD4+ T cells and has been 
shown to be important in tumor promotion (Langrish C., et al., 2004).  
IL-23 appears not only to induce innate inflammatory infiltration, but also to down 
regulate dramatically the ability of CD8 T cells to infiltrate tumors. 
 
To explore the respective importance of the host’s immune response to IL-12 and IL-
23 and to control tumor growth, Langowski and collaborators (Langowski J.L. et al., 
2006) challenged mice incapable of responding to IL-23 (IL23R-/- mice) with 
subcutaneous transplantation of murine tumor cell lines. The growth of B16F10 
melanoma and LL2 lung carcinoma was inhibited in IL23R-/- mice incapable of 
responding to IL-23, compared to either WT or mice incapable of responding to IL-12. 
 
Fig.2 Mechanisms of tumor promotion by deregulation of the IL-12/IL-23 family of 
cytokines (Langowski J.L. et al., Nature, 2006). 
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PGE2 molecule, an IL-12 inhibitor enabling MoDCs chemo taxis  
Prostaglandin E2 (PGE2) is a common inflammatory mediator known to exert Th2-
promoting and IL-12-antagonistic activity via several distinct mechanisms, affecting 
both APCs and Th cells. 
It suppresses the production of bioactive IL-12p70, both directly and by inhibiting the 
Th-cell production of IFN-γ, a key co-inducer of IL-12 during DCs-Th cells co-cultures 
(Hayes M.P., et al.; 1995; Murphy T.L., et al.; 1995; Ma X., et al.; 1996). Another 
example of IL-12-antagonistic and Th2-driving function of PGE2 is the induction of IL-
10, an inhibitor of bioactive IL-12p70 (D’Andrea A., et al.; 1993; Takenaka H., et al.; 
1997). PGE2 also inhibits the responsiveness of T cells to IL-12 down regulating the 
expression of the IL-12 receptor (Wu C.Y. et al.; 1998) and promoting the production 
of Th2 cytokines in murine and human Th clones.  
 
Although PGE2 enhances the expression of costimulatory molecules on DCs and 
increases their ability to stimulate CD4+ and CD8+ T cells (Kalinski P., et al., 1998; 
Rieser C., et al., 1997; Jonuleit H., et al., 1997), the ability of PGE2 to induce IL-
12p40 production and to suppress the IL-12p70-producing ability of DCs (Kalinski P., 
et al., 1997; Kalinski P., et al., 1998) may impair the tumoricidal functions of Th1, NK 
cells, and cytotoxic T lymphocytes.  
 
Of interest, recent results provide evidence that PGE2 is a general and mandatory 
factor for the development of a migratory phenotype of human MoDCs (Daniel F., et 
al., 2006).  
Whether the benefit of an enhanced migratory capacity of matured DCs by PGE2 is 
sufficient to offset its IL-12 antagonistic effects remain to be tested.  
 
 
1.6 TEM8: MARKER IN PROANGIOGENIC AND CELL MIGRATORY 
PROGRAMS 
Tumor endothelial marker (TEM8) was uncovered as a gene expressed 
predominantly in tumor endothelium, and its protein product was recently identified 
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as the receptor for anthrax toxin (ATRX1 /TEM8). (Carson-Walter E.B., et al., 2001; 
Bradley K.A., et al., 2003; Whittaker C.A., et al., 2002).  
 
The expression pattern of TEM8 was especially interesting in that it is the only 
human TEM characterized that shows undetectable mRNA expression in healing 
wounds and corpus luteum tissue, suggesting that this gene may be highly specific to 
tumor angiogenesis and not required for normal adult angiogenesis (St Croix et al. 
2000).  
 
However, TEM8 RNA is also expressed in a small proportion of the endothelial cells 
in normal brain, heart, intestines lung, skeletal muscle and pancreas, and at high 
levels in the endothelial cells of murine fetal liver and brain (St Croix et al. 2000, 
Carson-Walter E.B., et al. 2001). 
 
TEM8 encodes a type I transmembrane protein, 564 amino acids in length. The 
intracellular domain is 220 amino acids in length and the extra cellular region (aa 1-
318) contains a vWFA domain (aa 44-205) also known as an I-domain when present 
in integrins (Dickeson S.K., et al., 1998). Three different, apparently alternatively 
spliced, versions of the TEM8 gene have been described. The TEM8 variants share 
the same amino-terminal extra cellular part but differ in length and sequence in their 
putative cytosolic regions. Splice variant 1 (SV1) is the longest and is the original 
TEM8 cDNA that encodes a 564 amino acid protein with a long proline-rich 
cytoplasmic tail. Splice variant 2 (SV2) encodes a 368 amino acid protein with a short 
cytoplasmic tail. Splice variant 3 (SV3) encodes a protein that is identical to the other 
two throughout most of the extra cellular domain but diverges just before the 
transmembrane region such that it does not contain a recognizable membrane 
anchoring sequence. 
 
Interest in TEM8 variant 2 increased when it was identified as ATR, a cellular 
receptor for anthrax protective antigen (Bradley K.A., et al., 2001). ATR is identical to 
TEM8 for the first 364 amino acids, which includes the entire extracellular and 
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transmembrane domains, and then terminates after a 4 amino acid divergence from 
TEM8. 
 
Anthrax toxin, the major virulence factor produced by Bacillus anthraces, consists of 
three polypeptides called protective antigen (PA, 83 kDa), lethal factor (LF, 90 kDa), 
and edema factor (EF, 89kDa) (Leppla S.H., et al., 1999; Smith H., et al., 1962). The 
protective antigen mediates binding of the complex to TEM8 variant 2 (Bradley K.A., 
et al., 2001) whereas lethal factor and edema factor are responsible for eliciting 
toxicity.  
 
The identification of TEM8 as the anthrax receptor helped to clarify a potent 
antitumor response that had been previously obtained with anthrax toxin (Duesbery 
N.S., et al., 2001). Injection of the toxin into tumor-bearing mice led to a strong anti-
tumor response, in some cases causing complete tumor regression. Although the 
mechanism responsible was unclear at the time, an unexpected anti-angiogenic 
effect was postulated to be involved owing to the small number of vessels observed 
in the treated tumors. 
 
TEM8 interacts with the C5 domain of collagen α3 (VI), one of a limited number of 
transcripts preferentially expressed in tumor endothelium among 32,500 total 
transcripts analyzed (St. Croix B., et al., 2000). The interaction of these proteins and 
their coordinate expression in tumor endothelial cells suggests a functional role in 
angiogenesis. 
 
The large cytoplasmic tail of both the human and mouse TEM8 proteins share at 
least seven potential phosphorylation sites, supporting the hypothesis that TEM8 is 
involved in transmitting signals into the cell.  
 
Recently, capillary morphogenesis protein 2 (CMG2), the closet homologue to TEM8, 
was identified as a second receptor for anthrax toxin (ATRX2) (Scobie H.M., et al., 
2003). CMG2 sharing 51% amino acid identity with ATR/TEM8, in the I domain, and 
was identified originally in a screen for genes differentially regulated during capillary 
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induction in vitro. The CMG2 transcript was found to be up regulated early during the 
process of capillary morphogenesis (Bell S.E., et al., 2001), and the CMG2 protein 
was shown to bind to at least two extra cellular matrix (ECM) components, collagen 
IV and laminin. The sub cellular localization of CMG2 was determined to be 
predominantly in the endoplasmic reticulum. This finding suggests that CMG2 may 
be involved in the assembly of the basement membrane matrix that is produced 
during new blood vessel formation.  
 
The mRNA expression profile of ATR/TEM8 as well as mRNA expression and 
binding data of the highly similar protein, CMG2, suggest that one of the 
physiological roles of ATR/TEM8s may be in angiogenesis. However, the presence of 
ATR/TEM8 on the cell surface of most cell types tested in culture, on the tumor 
stroma as well as its presence on macrophages, indicates that there may be 
additional roles for this protein, perhaps in cellular adhesion.  
 
Many of the molecular mechanisms that mediate the relationship between 
inflammation, innate immunity and cancer progression remain to be defined. 
Tumour cells may usurp signalling molecules (i.e. integrins, chemokines and their 
receptors) by which innate immune system interfaces with cancers, for invasion, 
migration and metastasis (Muller A., et al., 2001). 
  
Many stages of the metastatic process resemble those of leukocyte homing to 
specific organs, raising the possibility that chemokines which are constitutively 
expressed at tumor metastatic sites direct the migration of the tumor cells to these 
organs. Indeed, it has been shown that the chemokine receptors CXCR4 and CCR7 
are highly expressed in human breast cancer cells and metastases, and the known 
ligands (CXCL12 and CCL21) of these receptors exhibit peak levels of expression in 
organs representing the first destination of breast cancer metastasis. 
  
When migrating tumor cells circulate in blood or lymph, they must adhere to 
endothelial cells before they can pass through the walls of blood or lymph vessels 
and into the adjacent tissues. The interaction of migrating tumor cells and endothelial 
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cells is thus of considerable importance in metastasis. So-called "adhesion 
molecules" are molecules expressed on the surface of a cell that mediate the 
adhesion of the cell to other cells or to the extracellular matrix. Adhesion molecules 
bind to receptors that are classed collectively as "integrins". 
 
Although TEM8 transcripts have been found to be selectively up regulated in tumor 
angiogenesis, analyses of TEM8 expression profiles and bioinformatics suggest that 
this presumptive tumor-specific endothelial marker gene may be highly specific in 
different cell types (like DCs and tumor cells) involved in extra cellular matrix-
remodeling and migration processes, such those observed in inflammatory reactions 
and tumor progression (Novatchkova M., Eisenhaber F., 2001). 
 
 
We therefore set out to investigate the angiogenic properties and TEM8 gene 
expression profiles of migratory standard clinical-grade monocyte-derived dendritic 
cells and of invasive and non-invasive human breast cancer cell lines. 
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2. AIM OF THE STUDY 
 
 
 
Monocyte-derived DCs (Mo-DCs) expressing tumor antigens are used in human 
clinical trials to induce therapeutic immunity against some neoplasms. 
However, a detailed understanding of the role that governs DCs migration and 
immuno-priming is still missing. 
 
Aim 1 of the present study has been to evaluate the proangiogenic and migratory 
properties of ex-vivo generated DCs activated by different maturation stimuli. 
 
 
 
Because TEM8 gene is specifically transcribed in different cell types involved in extra 
cellular matrix-remodeling and migration processes, and because tumor cells have 
co-opted some of the signalling molecules of innate immune system for invasion and 
metastases, we thought that TEM8 gene could be actively transcribed in both 
migratory DCs and invasive cancer cells.  
 
Aim 2 of the present study has been to quantitate TEM8 and CMG2 gene 
expressions in: 
 
i) migratory monocyte-derived dendritic cells (Mo-DCs) (matured with soluble 
mediators of the chronic inflammation) versus non migratory MoDCs. 
 
ii) invasive versus non-invasive human breast cancer cell lines.  
 
 
 
 
 
 23
  
 24 
3. MATERIAL AND METHODS 
 
 
3.1 DENDRITIC CELLS 
 
 
3.1.1 Patients 
The case series consisted of a subset of the 9 patients enrolled onto a phase I/II 
vaccination trial for advanced melanoma and renal cell carcinoma. The clinical trial 
was approved by the Italian Ministry of Health and by the Ethical Committee of Forlì 
Health and Social Services (Azienda USL-Forlì, Italy). All patients gave written 
informed consent. 
 
 
3.1.2 DCs generation 
DCs were prepared from peripheral blood monocytes (PBMC) obtained by 
leukapheresis without previous mobilization. 5–9 litres of blood were processed in 
each collection. PBMC were purified on Ficoll-Plaque, and incubated in tissue culture 
flasks with CellGro DC Medium (Cell Genix, Freiburg, Germany) at 10 x 106 cells/ml 
for 2 h.  
The non-adherent cells were discarded and the adherent cells were incubated in 
CellGro DC Medium containing 1000 IU/ml rhIL-4 (Cell Genix) and 1000 IU/ml rhGM-
CSF (Shering Plough, Milan, Italy) for 7 days to generate a DCs-enriched cell 
population. On day 7, they were defined as iDCs. After eliminating the previous 
culture medium, iDCs were cultured for a further 2 days with a cocktail of cytokines 
(TNF-α, IL-1β, IL-6, Endogen, Pierce Biotechnology, Rockford, USA, PGE2, Cayman 
Chemical, Ann Arbor, MI, USA).  
Moreover, iDCs were cultured with the PGE2-depleted cocktail or with TNF-α, IL-1β, 
IL-6 and Poly I:C (Amersham Biosciences). On day 9 they were defined as mDCs.  
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3.1.3 Phenotype analysis 
iDCs and mDCs phenotypes were determined by single or two-color fluorescence 
analysis. 3–5·105 cells were suspended in 100 µl of buffer (PBS, 2% FCS, 1% 
sodium azide) and incubated for 30 min at 4°C with 10 µl of appropriate fluorescein 
isothiocyanate or phycoerythrin-labelled monoclonal antibodies (mAbs). The cells 
were then washed twice and resuspended in 500 µl of PBS. The fluorescence was 
analyzed by a FACS Vantage flow cytometer (Becton Dickinson, Milan, Italy). mAbs 
specific for human CD1a, CD14, CD80, CD86, CD11c, CD33, DR (Becton 
Dickinson), CD83 (Immunotech, Marseille, France) and CCR7 (BD Pharmingen, 
Milan, Italy) were used. 
 
 
3.1.4 DCs labelling and migration evaluation 
Labelling of DCs was performed according to the methods described for leukocyte 
radiolabelling (Peters A.M., 1988; Costa D.C., 1988; McAfee J.G. 1984). A part of 
both iDCs and mDCs destined for vaccination (about 9.106) were resuspended in 
platelet-poor autologous plasma (CFP1) and incubated for 15 min at room 
temperature with 111In-Oxine (1 mCi) (Altana Pharma, Milan, Italy). After two 
washes to eliminate the unbound isotope, the cells were resuspended in a total 
volume of 1.5 ml of CFP1.  
 
Radiolabelling of DCs and of the culture supernatant was evaluated with a gamma 
counter, after which DCs were inoculated intradermally into the patient near healthy 
lymph nodes and in the controlateral zone not used for therapeutic vaccination (3 
inoculations at 10 cm from inguinal or axillary lymph nodes). The patient then 
underwent serial acquisitions with gamma-camera positioned at the site of 
inoculation, with a field of view that included all the lymphatic regions of interest. The 
first acquisition was performed with a dynamic study of 20 min, followed by 10-min 
static acquisitions carried out every 30 min for the first 4–6 h and from 18 to 28 h. 
Other static determinations were made at 36, 48 and 72 h. The maximum duration of 
observation of DCs migratory activity, which depended on the half-life of the 
radioisotope used, was 72 h for 111In-Oxine.  
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 The identification of lymph node stations involved in the migratory activity was initially 
visual, after which we carried out a semiquantitative evaluation of the percentage of 
DCs that migrated to lymph nodes from the inoculation site and an assessment of the 
speed of DCs migration, expressed by activity/time curves obtained through the 
compartmental mathematical model. 
 
 
3.1.5 Evaluation of labelling stability 
DCs obtained from the culture of frozen PBMC were labelled with 111In-Oxine. The 
labelled cells were then suspended in CellGro DC Medium, divided into 4–5 culture 
flasks and incubated for 0 h, 4 h, 21 h, 24 h, 48 h (111In-Oxine). The DCs from one 
flask were removed and centrifuged. The supernatant containing the free molecule, 
and the pellet containing the labelled cells, were then measured with a gamma 
counter. 
 
 
3.1.6 Cytokine production 
At each pre-set time the supernatants of iDCs and mDCs were collected and stored 
at -80°C until analysis was carried out using commercially available ELISA Kit 
(Biosource, Nivelles, Belgium) to measure the production of IL-12p40, IL-12p70 and 
IL-10, Endogen Human VEGF Elisa Kit (Pierce Biotechnology) to measure the 
production of VEGF165 and VEGF121 isoforms and Bender MedSystem human IL-23 
ELISA to measure the production of IL-23 according to the manufacture's protocols. 
 
 
3.1.7 TSP Measurement 
The quantitative measurement of Thrombospondin-1 in culture supernatants was 
carried out using ChemiKine Human TSP-1 EIA Kit (Product #CYT168, Chemicon 
International). 
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Pre-coated goat anti-rabbit antibody plates are used to capture a specific TSP-1 
complex in each sample consisting of TSP-1 antibody, biotinylated TSP-1 and 
sample/standard. 
The biotinylated TSP-1 conjugate (competitive ligand) and sample or standard 
compete for TSP-1 specific antibody binding sites. Therefore, as the concentration of 
TSP-1 in the sample increases, the amount of biotinylated TSP-1 capture by the 
antibody decreases. The assay is visualized using a streptavidin alkaline 
phosphatase conjugate and an ensuing chromagenic substrate reaction. The amount 
of TSP-1 detected in each sample is compared to a TSP-1 standard curve which 
demonstrates an inverse relationship between Optical Density (O.D.) and cytokine 
concentration. 
 
 
3.1.8 h-HGF Measurement 
The quantitative measurement of h-HGF in culture supernatants was carried out 
using   Quantikine Human HGF Immunoassay (Product #DHG00, R&D Systems). 
This assay employs the quantitative sandwich enzyme immunoassay technique. A 
monoclonal antibody specific for HGF has been pre-coated onto a microplate. 
Standards and samples are pipetted into the wells and any HGF present is bound by 
the immobilized antibody. After washing away any unbound substances, an enzyme-
linked polyclonal antibody specific for HGF is added to the wells. Following a wash to 
remove any unbound antibody-enzyme reagent, a substrate solution is added to the 
wells and color develops in proportion to the amount of HGF bound in the initial step. 
The color development is stopped and the intensity of the color is measured. 
 
 
3.1.9 RNA isolation and complementary DNA synthesis  
Total RNA was isolated from monocytes, immature and mature (with standard 
cocktail, PGE2-depleted cocktail or cocktail + Poly I:C) human MoDCs, obtained from 
patients. 
The cells (5x105) were lysed by incubation with a lyses buffer that immediately 
inactivates RNase and creates appropriate binding conditions which favour 
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adsorption of RNA to the silica membrane. Contaminating DNA is removed by a 
DNase I solution which is directly applied onto the silica membrane during the 
preparation. Simple washing steps with two different buffers remove salts, 
metabolites and macromolecular cellular components. Pure RNA is eluted under low 
ionic strength conditions with RNase-free water. 
The concentration of RNA was determined spectrophotometrically by measuring 
absorbance at 260nm and RNA integrity was confirmed by electrophoresis on a 1,2% 
agarose gel. 
 
We used 1 µg of total RNA for synthesis of first-strand complementary DNA (cDNA) 
by RevertAid H Minus First Strand cDNA Syntesis Kit (Fermentas, Life Sciences).  
The RNA (1 µg) was incubated with H2O and 1µl of Oligo dT Primer (0,5µg/µl) for 5 
minutes at 70°C. At the reaction were added 2µl of 10x Reaction Buffer, the RNAsi 
inhibitor and 2µl of 10nM dNTPs mix. The reaction mixture was heated to 37°C for 5 
minutes.  
At the reaction was then added 1µl of the RevertAid H Minus M-MuLV Reverse 
Transcriptase (200u/µl) (final volume 20 µl) and incubated for 60 minutes at 42°C. 
Reaction was heated to 70°C for 10 minutes to inactivate Reverse Transcriptase.  
The resulting cDNA was used for qualitative reverse-transcription polymerase chain 
reaction (RT-PCR) and for quantitative Real-Time PCR.  
 
 
3.1.10 Qualitative RT-PCR 
One µl of reverse-transcription reactions of iDCs and standard cocktail, PGE2-
depleted cocktail or cocktail + Poly I:C treated-mDCs was used as target in a PCR 
reaction to amplify the IL-12p40 (354 bp), IL-12p35 (358 bp) and IL-23p19 (224 bp) 
subunits. 
 
Primers used: 
IL-12p40 FW: CCAAgAACTTgCAgCTgAAg 
IL-12p40 RV: TgggTCTATTCCgTTgTgTC 
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IL-12p35 FW: AACTAATgggAgTTgCCTgg 
IL-12p35 RV: ggACCTCgCTTTTTAggAAg 
 
IL-23p19 FW: ggCATgAAgTTACAgTgTgTTTCC 
IL-23p19 RV: ACATCTAAgggCTTAATgATCTgC 
 
One µl of reverse-transcription reactions of the monocytes and dendritic cells was 
then used as target in a PCR reaction to amplify  either the extra cellular and 
transmembrane domain of human TEM8 (AF279145) (594 bp fragment) or a portion 
of the extra cellular domain of human capillary morphogenesis protein 2 (AY233452) 
(200 bp fragment). 
The TEM8 and CMG2 transmembrane domains are indicated in blue. 
 
Primers used: 
hTEM8FW: TgAAgATCTCTTTTTCTATTCAgAgAgggA 
hTEM8RV: TTgATAATCACAgTgCAgCAgAgggg 
 
 
CDS TEM8: 144..1838 
 
 
                144 atggcca cggcggagcg gagagccctc ggcatcggct 
      181 tccagtggct ctctttggcc actctggtgc tcatctgcgc cgggcaaggg ggacgcaggg 
      241 aggatggggg tccagcctgc tacggcggat ttgacctgta cttcattttg gacaaatcag 
      301 gaagtgtgct gcaccactgg aatgaaatct attactttgt ggaacagttg gctcacaaat 
      361 tcatcagccc acagttgaga atgtccttta ttgttttctc cacccgagga acaaccttaa 
      421 tgaaactgac agaagacaga gaacaaatcc gtcaaggcct agaagaactc cagaaagttc 
      481 tgccaggagg agacacttac atgcatgaag gatttgaaag ggccagtgag cagatttatt 
      541 atgaaaacag acaagggtac aggacagcca gcgtcatcat tgctttgact gatggagaac 
      601 tccatgaaga tctctttttc tattcagaga gggaggctaa taggtctcga gatcttggtg 
      661 caattgttta ctgtgttggt gtgaaagatt tcaatgagac acagctggcc cggattgcgg 
      721 acagtaagga tcatgtgttt cccgtgaatg acggctttca ggctctgcaa ggcatcatcc 
      781 actcaatttt gaagaagtcc tgcatcgaaa ttctagcagc tgaaccatcc accatatgtg 
      841 caggagagtc atttcaagtt gtcgtgagag gaaacggctt ccgacatgcc cgcaacgtgg 
      901 acagggtcct ctgcagcttc aagatcaatg actcggtcac actcaatgag aagccctttt 
      961 ctgtggaaga tacttattta ctgtgtccag cgcctatctt aaaagaagtt ggcatgaaag 
     1021 ctgcactcca ggtcagcatg aacgatggcc tctcttttat ctccagttct gtcatcatca 
     1081 ccaccacaca ctgttctgac ggttccatcc tggccatcgc cctgctgatc ctgttcctgc  
     1141 tcctagccct ggctctcctc tggtggttct ggcccctctg ctgcactgtg attatcaagg 
     1201 aggtccctcc accccctgcc gaggagagtg aggaagaaga tgatgatggt ctgcctaaga 
     1261 aaaagtggcc aacggtagac gcctcttatt atggtgggag aggcgttgga ggcattaaaa 
     1321 gaatggaggt tcgttgggga gaaaagggct ccacagaaga aggtgctaag ttggaaaagg 
     1381 caaagaatgc aagagtcaag atgccggagc aggaatatga attccctgag ccgcgaaatc 
     1441 tcaacaacaa tatgcgtcgg ccttcttccc cccggaagtg gtactctcca atcaagggaa 
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     1501 aactcgatgc cttgtgggtc ctactgagga aaggatatga tcgtgtgtct gtgatgcgtc 
     1561 cacagccagg agacacgggg cgctgcatca acttcaccag ggtcaagaac aaccagccag 
     1621 ccaagtaccc actcaacaac gcctaccaca cctcctcgcc gcctcctgcc cccatctaca 
     1681 ctcccccacc tcctgcgccc cactgccctc ccccgccccc cagcgcccct acccctccca 
     1741 tcccgtcccc accttccacc cttccccctc ctccccaggc tccacctccc aacagggcac 
     1801 ctcctccctc ccgccctcct ccaaggcctt ctgtctag  
      
 
Primers used: 
hCMG2FW: gTgTTTATTgTgTTggTgTCCTTg 
hCMG2RV: gACAATCTgAAATTCCTCCCC 
 
 
CDS CMG2: 4..1470 
 
 
 
 1 aggatggtgg cggagcggtc cccggcccgc agccccggga gctggctgtt ccccgggctg 
       61 tggctgttgg tgctcagcgg tcccgggggg ctgctgcgcg cccaggagca gccctcctgc 
      121 agaagagcct ttgatctcta cttcgtcctg gacaagtctg ggagtgtggc aaataactgg 
      181 attgaaattt ataatttcgt acagcaactt gcggagagat ttgtgagccc tgaaatgaga 
      241 ttatctttca ttgtgttttc ttctcaagca actattattt tgccattaac tggagacaga 
      301 ggcaaaatca gtaaaggctt ggaggattta aaacgtgtta gtccagtagg agagacatat 
      361 atccatgaag gactaaagct agcgaatgaa caaattcaga aagcaggagg cttgaaaacc 
      421 tccagtatca taattgctct gacagatggc aagttggacg gtctggtgcc atcatatgca 
      481 gagaaagagg caaagatatc caggtcactt ggggctagtg tttattgtgt tggtgtcctt 
      541 gattttgaac aagcacagct tgaaagaatt gctgattcca aggagcaagt tttccctgtc 
      601 aaaggtggat ttcaggctct taaaggaata attaattcta tactagctca gtcatgtact 
      661 gaaatcctag aattgcagcc ctcaagtgtc tgtgtggggg aggaatttca gattgtctta 
      721 agtggaagag gattcatgct gggcagtcgg aatggcagtg ttctctgcac ttacactgta 
      781 aatgaaacat atacaacgag tgtaaaacca gtaagtgtac agcttaattc tatgctttgt 
      841 cctgcaccta tcctgaataa agctggagaa actcttgatg tttcagtgag ctttaatgga 
      901 ggaaaatctg tcatttcagg atcattaatt gtcacagcca cagaatgttc taacgggatc 
      961 gcagccatca ttgttatttt ggtgttactg ctactcctgg ggatcggttt gatgtggtgg 
     1021 ttttggcccc tttgctgcaa agtggttatt aaggatcctc caccaccacc cccccctgca 
     1081 ccaaaagagg aggaagaaga acctttgcct actaaaaagt ggccaactgt ggatgcttcc 
     1141 tattatggtg gtcgaggggt tggaggaatt aaaagaatgg aggttcgttg gggtgataaa 
     1201 ggatctactg aggaaggtgc aaggctagag aaagccaaaa atgctgtggt gaagattcct 
     1261 gaagaaacag aggaacccat caggcctaga ccacctcgac ccaaacccac acaccagcct 
     1321 cctcagacaa aatggtacac cccaattaag ggtcgtcttg atgctctctg ggctttgttg 
     1381 aggcggcagt atgaccgggt ttctttgatg cgacctcagg aaggagatga ggtttgtata 
     1441 tgggaatgta ttgagaaaga gctaactgct 
 
 
   
The PCR conditions were an initial denaturation at 95°C for 5 minutes, 35 cycles at 
95°C for 1 minute, 63°C for 1 minute (to amplify extra cellular hTEM8), 60°C for 1 
minute (to amplify hCMG2), 62°C for 1 minute (to amplify p40 and p35) or 63°C for 1 
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minute (to amplify p19), 72°C for 1 minute and than, after 35 cycles, 10 minutes of 
incubation at 72ºC. PCR reactions were performed using a thermal cycler (Biorad). 
The PCR products were separated by horizontal gel electrophoresis in 1,2% 
agarose/ethidium bromide (10mg/ml). PCR products were run for approximately 60 
minutes at 90 volt, visualised using a UV transilluminator (Biorad) and photographed.  
 
As internal control to assess the integrity of the different RNAs and to confirm the 
success of the reverse-transcription reaction, primers for housekeeping gene 
GADPH (glyceraldehyde phosphate dehydrogenase) were used in the reaction of 
amplification. 
 
The primers used are:  
Fw GADPH: CAACAgCgACACCCACTCCT  
Rev GADPH: AggCCATgTgggCCATgA 
 
 
3.1.11 DNA sequencing 
To confirm the specific amplification of the extracellular and transmembrane domain 
of human TEM8 and the portion of the extra cellular domain of human capillary 
morphogenesis protein 2, DNA sequencing was performed on PCR products from 
each different sample monocytes, iDCs and mDCs. The PCR bands were excised 
from the agarose gel, purified with Macherey-Nagel gel extraction columns and 
sequenced in both orientations. The sequencing reactions were carried out by MWG 
Biotech/M-Medical (Germany).  
 
 
3.1.12 Quantitative Real-Time PCR  
One µl of reverse-transcription reactions of monocytes, iDCs and standard cocktail or 
cocktail + Poly I:C treated-mDCs was used as target in a Quantitative Real Time 
PCR. 
Real-time RT-PCR was performed by means of the MX3000P Real-time PCR system 
(Stratagene) and the BRILLIANT SYB Green QPCR Master mix according to the 
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protocol provided by the manufacturer. After initial denaturation for 10 minutes at 
95°C, thermal cycling was performed for 40 cycles with steps of 94°C for 48 seconds, 
60°C for TEM8 and CMG2, 62°C for p40 and p35, 64°C for p19, for 48 seconds, and 
72°C for 48 seconds, with the fluorescence being read at the end of each cycle. The 
following oligonucleotides were used as primers for the Quantitative PCR:  
 
p40 and p35: same primers used in Qualitative RT-PCR 
 
p19: same primers used in Qualitative RT-PCR 
 
TEM8:  
FW: ACAgggTCCTCTgCAgCTTCAA 
Rev: gTCAgAACAgTgTgTggTggTgAT 
 
These primers are used to amplify a portion of the extra cellular domain of human 
TEM8 (200bp fragment). 
The TEM8 transmembrane domain is indicated in blue. 
 
CDS TEM8: 144..1838 
 
 
                144 atggcca cggcggagcg gagagccctc ggcatcggct 
      181 tccagtggct ctctttggcc actctggtgc tcatctgcgc cgggcaaggg ggacgcaggg 
      241 aggatggggg tccagcctgc tacggcggat ttgacctgta cttcattttg gacaaatcag 
      301 gaagtgtgct gcaccactgg aatgaaatct attactttgt ggaacagttg gctcacaaat 
      361 tcatcagccc acagttgaga atgtccttta ttgttttctc cacccgagga acaaccttaa 
      421 tgaaactgac agaagacaga gaacaaatcc gtcaaggcct agaagaactc cagaaagttc 
      481 tgccaggagg agacacttac atgcatgaag gatttgaaag ggccagtgag cagatttatt 
      541 atgaaaacag acaagggtac aggacagcca gcgtcatcat tgctttgact gatggagaac 
      601 tccatgaaga tctctttttc tattcagaga gggaggctaa taggtctcga gatcttggtg 
      661 caattgttta ctgtgttggt gtgaaagatt tcaatgagac acagctggcc cggattgcgg 
      721 acagtaagga tcatgtgttt cccgtgaatg acggctttca ggctctgcaa ggcatcatcc 
      781 actcaatttt gaagaagtcc tgcatcgaaa ttctagcagc tgaaccatcc accatatgtg 
      841 caggagagtc atttcaagtt gtcgtgagag gaaacggctt ccgacatgcc cgcaacgtgg 
      901 acagggtcct ctgcagcttc aagatcaatg actcggtcac actcaatgag aagccctttt 
      961 ctgtggaaga tacttattta ctgtgtccag cgcctatctt aaaagaagtt ggcatgaaag 
     1021 ctgcactcca ggtcagcatg aacgatggcc tctcttttat ctccagttct gtcatcatca 
     1081 ccaccacaca ctgttctgac ggttccatcc tggccatcgc cctgctgatc ctgttcctgc  
     1141 tcctagccct ggctctcctc tggtggttct ggcccctctg ctgcactgtg attatcaagg 
     1201 aggtccctcc accccctgcc gaggagagtg aggaagaaga tgatgatggt ctgcctaaga 
     1261 aaaagtggcc aacggtagac gcctcttatt atggtgggag aggcgttgga ggcattaaaa 
     1321 gaatggaggt tcgttgggga gaaaagggct ccacagaaga aggtgctaag ttggaaaagg 
     1381 caaagaatgc aagagtcaag atgccggagc aggaatatga attccctgag ccgcgaaatc 
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     1441 tcaacaacaa tatgcgtcgg ccttcttccc cccggaagtg gtactctcca atcaagggaa 
     1501 aactcgatgc cttgtgggtc ctactgagga aaggatatga tcgtgtgtct gtgatgcgtc 
     1561 cacagccagg agacacgggg cgctgcatca acttcaccag ggtcaagaac aaccagccag 
     1621 ccaagtaccc actcaacaac gcctaccaca cctcctcgcc gcctcctgcc cccatctaca 
     1681 ctcccccacc tcctgcgccc cactgccctc ccccgccccc cagcgcccct acccctccca 
     1741 tcccgtcccc accttccacc cttccccctc ctccccaggc tccacctccc aacagggcac 
     1801 ctcctccctc ccgccctcct ccaaggcctt ctgtctag  
 
 
CMG2: same primers used in Qualitative RT-PCR 
 
Analysis was performed with MxPro QPCR Software version 3.00 for MX3000P. The 
obtained values were within the linear range of a standard curve and were 
normalized to yield the same amount of glyceraldehyde phosphate dehydrogenase 
(GAPDH) messenger RNA (mRNA) (Fw GADPH: CAACAgCgACACCCACTCCT and 
Rev GADPH: AggCCATgTgggCCATgA). All PCR products were analyzed by 
determination of melting profiles as well as by agarose gel electrophoresis.  
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3.2 HUMAN BREAST CANCER CELL LINES 
 
In the experiments we used different breast cancer cell lines obtained from American 
Type Culture Collection (ATCC).  
 
MDA-MB231
Was obtained from a pleural effusion of a 51 year old white female. With epithelial-
like morphology, the cells appear phenotypically as a spindle shaped cells. In vitro, 
the MDA-MB231 cell line has an invasive phenotype (Thompson E.W., et al., 1992). 
In vivo, the MDA-MB231 cells form mammary fat pad tumors in nude mice with a 
suggested tumorigenic dose of 2.5 x 106 (Mukhopadhyay R., et al., 1999). Iv injection 
of 1x106 cells into the tail vein of nude mice has been shown to produce experimental 
metastasis (Mukhopadhyay R., et al., 1999). 
The cell line is aneuploid female (modal number = 64, range = 52 to 68), with 
chromosome counts in the near-triploid range.  
 
SkBr3
Was obtained from a pleural effusion of a 43 year old Caucasian woman. In vitro, the 
cell line has low chemoinvasion and chemotaxis activity (Thompson E.W., et al., 
1992). Two publications report SkBr3 as being non-tumorigenic in nude mice, but a 
more recent paper showed tumorigenesis with an injection of 1x106 cells into the 
mammary fat pad (Thompson E.W., et al., 1992; Van Slooten H.J., et al., 1995; 
Zimonjic D.B., et al., 2000). 
This is a hypertriploid human cell line with the modal chromosome number of 84, 
occurring in 34% of cells.  
 
ZR75-1 
Was obtained from an ascites of a 63 year old Caucasian woman. In vitro, the Zr75-1 
cell line has a non-invasive phenotype. The cells are capable of forming tumors in the 
mammary fat pad of nude mice (Thompson E.W., et al., 1992; Zimonjic D.B., et al., 
2000). A suggested tumorigenic dose is 1-2x 106 cells (Thompson E.W., et al., 1992; 
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Zimonjic D.B., et al., 2000). Spontaneous metastasis from tumors in mammary fat 
pad has not been reported (Thompson E.W., et al., 1992). 
This cell line has a hypertriploid chromosome number. The modal chromosome 
number was 72 occurring in 26% of the cells and the rate of higher ploidies was at 
1,2%. 
 
These cell lines were maintained at 37°C in a humidified 5% CO2 environment in 
Dulbecco’s modified Eagles medium (D-MEM) (Cambrex) with 1% L-glutamine, 1% 
penicillin/streptomycin, supplemented (growing condition) or not (starving condition) 
with 10% foetal bovine serum (FBS) (Cambrex).  
Cells were trypsinized and used for proteic lysate or RNA extraction. 
 
 
3.2.1 Chemokine receptors analysis 
Chemokine receptors in human breast cancer cell lines were determined by two-color 
fluorescence analysis. 3–5·105 cells were suspended in 100 µl of buffer (PBS, 2% 
FCS, 1% sodium azide) and incubated for 30 min at 4°C with 10 µl of appropriate 
fluorescein isothiocyanate or phycoerythrin-labelled monoclonal antibodies (mAbs). 
The cells were then washed twice and resuspended in 500 µl of PBS. The 
fluorescence was analyzed by a FACS Vantage flow cytometer (Becton Dickinson, 
Milan, Italy). mAbs specific for human CCR7 and CXCR4 (BD Pharmingen, Milan, 
Italy) were used. 
 
 
3.2.2 VEGF-A and PGE2 production 
The supernatants of MDA-MB231, Zr75-1 and SkBr3 were collected and was carried 
out an ELISA assay by Endogen Human VEGF Elisa Kit (Pierce Biotechnology) to 
measure the production of VEGF-A, according to the manufacture’s protocols. 
The levels of PGE2 released in supernatants were measured using a PGE2 enzyme 
immunoassay kit from Cayman Chemicals according to the manufacture's protocols. 
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3.2.3 Cell lysates 
Cultured cells were collected by low-speed centrifugation at room temperature for 5 
minutes. After removal of culture media, the cell pellet was washed twice with cold 
PBS. Whole lysates were prepared by incubating 107 cells per ml Ripa buffer (25mM 
Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% Na deoxicolate, 0.1% SDS, 100 
µg/ml phenylmethylsulfonyl flouride PMSF, 1mM Na-Vanadate, 2µg/ml aprotinin, 
1µg/ml leupeptin and 1µg/ml pepstatin) for 30 minutes on ice. Lysates were cleared 
by centrifugation at 12.000 x g for 10 minutes at 4°C. The supernatant fluid was 
transferred to a new microfuge tube and the pellet was discarded. Protein 
concentration was determined by Bradford protein assay (Biorad). 
 
 
3.2.4 Western Blot analysis 
Electrophoretic assays of cell lysates were performed using the Bio-Rad 
electrophoretic system. 50 µg of protein samples in loading buffer were heated at 
100°C for 5 minutes and loaded on 7,5% SDS-PAGE. After electrophoresis and 
electro-transfer, the nitrocellulose membrane (PROTRAN Schleicher & Schuell) was 
blocked with 1% non fat-dry milk (Biorad) in TBS-T for 1 hour. The membranes were 
probed with monoclonal antibodies against Vimentin, Tenascin-C and E-cadherin for 
1 hour at 37°C or overnight at 4°C. Bound antibodies were detected using 
appropriate secondary antibodies (Calbiochem) for 1 hour at 37°C or overnight at 
4°C, and visualized with a commercial ECL kit (Amersham). 
 
 
3.2.5 RNA isolation and complementary DNA synthesis  
Total RNA was isolated from 1x106  breast cancer cells (MDA-MB231, SkBr3, Zr75-
1) following the same protocol used for dendritic cells.  
The resulting cDNA was used in Qualitative reverse-transcription polymerase chain 
reaction (RT-PCR) and in Quantitative Real-Time PCR.  
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3.2.6 Qualitative RT-PCR 
One µl of reverse-transcription reactions of the breast cancer cells was then used as 
target in a PCR reaction to amplify a portion of the extra cellular domain of human 
TEM8 (AF279145) (200 bp fragment). 
 
Primers used are: 
FW: ACAgggTCCTCTgCAgCTTCAA 
Rev: gTCAgAACAgTgTgTggTggTgAT 
 
The PCR conditions were an initial denaturation at 95°C for 5 minutes, 20 cycles at 
95°C for 1 minute, 63°C for 1 minute and 72°C for 1 minute. After the last cycle, there 
was final 10 minutes of incubation at 72ºC. PCR reactions were performed using a 
thermal cycler (Biorad). 
The PCR products were separated by horizontal gel electrophoresis in 1,2% 
agarose/ethidium bromide (10mg/ml). PCR products were run for approximately 60 
minutes at 90 volt, visualised using a UV transilluminator (Biorad) and photographed.  
 
As internal control to assess the integrity of the different RNAs and to confirm the 
success of the reverse-transcription reaction, primers for housekeeping gene 
GADPH (glyceraldehyde phosphate dehydrogenase) were used in the reaction of 
amplification. 
 
Primers used are:  
Fw GADPH: CAACAgCgACACCCACTCCT  
Rev GADPH: AggCCATgTgggCCATgA 
 
 
3.2.7 DNA sequencing 
To confirm the specific amplification of a portion of the extra cellular domain of 
human TEM8, DNA sequencing was performed on PCR products from each different 
sample (MDA-MB231, SKBr3, and ZR75-1). The PCR bands were excised from the 
agarose gel, purified with Macherey-Nagel gel extraction columns and sequenced in 
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both orientations. The sequencing reactions were carried out by MWG Biotech/M-
Medical (Germany).  
 
 
3.2.8 Quantitative Real-Time PCR  
Real-time RT-PCR protocol and the primers used for TEM8, CMG2 and GADPH are 
the same used in Real-Time PCR for dendritic cells. 
 
 
3.2.9 Breast cancer cell lines treatment 
Human metastatic breast cancer cell lines were maintained in culture for 24h as 
previously described. Then the MDA-MB231, Zr75-1 and SkBr3 cells were stimulated 
in growing and starving conditions with the cytokine cocktail (TNF-α 20ng/ml, IL-1β 
20ng/ml, IL-6 2000UI/ml, PGE2 1µg/ml). 
The SkBr3 cells were also stimulated in starving conditions with the PGE2 depleted 
cocktail, only PGE2, only IL-6, IL-1β+TNF-α, IL-6+IL-1β and IL-6+TNF-α. 
 
After 48h, culture media was removed and total RNA was extracted.  
We used 1 µg total RNA for synthesis of first-strand complementary DNA. The 
resulting cDNA was used to determine the TEM8 and CMG2 gene expressions by 
qualitative and quantitative RT-PCR, following the same protocol used for dendritic 
cells. 
MDA-MB231, SKBr3 and ZR75-1 were photographed (unstimulated and after 48h of 
stimulation with the cytokines cocktail) by Nikon Eclipse TS100 microscopy.  
 
 
3.2.10 Actin polymerization assay 
The cells MDA-MB231, SkBr3 and Zr75-1 (3x106) were plated in media without FBS 
on polylysined coverslip in 100 mm dishes and incubated for 24 hours. Cell cultures 
were untreated or treated with cytokine cocktail (TNF-α 20ng/ml, IL-1β 20ng/ml, IL-6 
2000UI/ml, PGE2 1µg/ml).  
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After 48h, cells were fixed on polylysined coverslip in 3% paraformaldehyde; after 
washing in PBS (6 times) cells were permeabilized for 5 min. with 0,2% TRITON X-
100 in PBS. After washing (twice) in PBS each sample was incubated with PBS 1% 
BSA for 20-30 min. Subsequently, each sample was incubated for 30 to 45 min. with 
fluorescein isothiocyanate (FITC)-labelled phalloidin (Molecular Probes, #F432) 
diluted in PBS 1% BSA. 
Fixed cells were washed 6 times in PBS and confocal images were acquired at the 
confocal laser scan microscopy (BIORAD MRC 600). 
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4. RESULTS 
 
 
4.1 DENDRITIC CELLS 
 
4.1.1 DCs PHENOTYPE ANALYSIS 
To activate T cells in vivo, DCs increase their expression of HLA-DR, CD80, CD83 
and CD86 molecules in response to a variety of maturation stimuli. Two maturation 
cocktails, consisting of either TNF-α, IL-1β, IL-6 and PGE2 or TNF-α, IL-1β, IL-6 and 
Poly I:C, were evaluated for the ability to induce phenotypic changes associated with 
maturation in DCs from melanoma and renal carcinoma patients. 
iDCs and mDCs were analyzed by single or two-color fluorescence analysis; the 
fluorescence was measured by a FACS Vantage flow cytometer.  
Monoclonal antibodies were used against the following antigens: CD1a, CD14, 
CD11c, CD33, CD80, CD86, DR, CD83, and CCR7.  
Data about iDCs and mDCs markers are reported in table 1 and figure 1.  
 
As expected the fraction of mDCs expressing CD1a+ and CD14+ antigens, markers 
for Langerhans cells and monocytes respectively (table 1), was low (3%), while 80% 
of mDCs (data not shown) showed a myeloid phenotype (either/both CD11c+ or/and 
CD33+ expression).  
 
Both maturation cocktails increased the fraction of cells expressing HLA-DR, CD80, 
CD86 and CD83, molecules which are necessary to activate T cells in vivo. However, 
a considerable difference between the two maturation cocktails was observed: 
significant expression of the chemokine receptor CCR-7, necessary for homing of 
DCs to draining lymph nodes, was induced by TNF-α, IL-1β, IL-6 + PGE2  (table 1 
and figure 1), while TNF-α, IL-1β, IL-6 + Poly I:C treatment did not (table 1). 
The finding suggests that lack of CCR-7 up-regulation during maturation with Poly I:C 
might be the consequence of the fact that prostaglandin E2 is a major inducer of this 
receptor (Scandella E. et al., 2002). 
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4.1.2 DCs MIGRATORY PHENOTYPE  
In vivo, DCs migration was investigated in iDCs and cytokine-cocktail (TNF-α, IL-1β, 
IL-6 and PGE2) matured DCs in terms of migration time and cells number to draining 
lymph nodes (figures 2 and 3). 
 
DCs labelling efficiency and stability 
The in vitro stability of DCs labelled with 111In-Oxine was evaluated using DCs 
cultured from frozen PBMC. 
Indium has a low intensity but a long half-life, which enabled us to monitor the 
migration activity of labelled DCs for up to 72h. 
111In-Oxine-labelled DCs showed a high labelling stability (50%) that lasted for up to 
24 h. 
 
iDCs/mDCs migration 
Data shown in figures 2 and 3 refer to 4 groups of patients treated with mature or 
immature cells labelled with 111In-Oxine.  
A lymph node uptake of DCs has been monitored in all patients within the first two 
hours of inoculation; the uptake percentage continued to increase for the entire 
temporal range studied (48–60 h). A curve fitting analysis further suggests a 
progressive increase in uptake after the first 60 h; however the number of patients 
evaluated is too low for any definitive conclusions to be drawn. 
The result showed a greater progressive concentration of mDCs to regional lymph 
node, six-eightfold higher than iDCs (figures 2 and 3) in accordance with data 
reported by others (Morse M.A., et al., 1999; De Vries I.J., et al., 2003). 
  
The results obtained in this study bear witness to the fact that mDCs exhibit a much 
higher CCR7 surface expression than iDCs (86% vs. 4%; table 1). 
 
 
4.1.3 DCs PRO-ANGIOGENIC PHENOTYPE  
Recently, human myeloid dendritic cells matured with LPS in the presence of anti-
inflammatory molecules, such as IL-10 or PGE2 (LPS+IL-10 or LPS+PGE2), have 
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been reported to selectively secrete the potent angiogenic cytokine vascular 
endothelial growth factor A (VEGF-A) in vitro and to posses proangiogenic activity in 
vivo (Riboldi E. et al., 2005). 
 
Accordingly we evaluated the pro-angiogenic potential of DCs measuring (ELISA 
assay) the levels of VEGF-A in different culture media: 
 
- immature DCs;  
- DCs matured with IL-1β, IL-6, TNF-α and PGE2; 
- DCs matured with IL-1β, IL-6, TNF-α and Poly I:C;  
- DCs matured with IL-1β, IL-6 and TNF-α.  
 
VEGF is produced in multiple isoforms by alternative splicing of a single gene, with 
VEGF 121 and VEGF165 being the most common variants. Figure 4 shows that the 
production of VEGF (both VEGF 165 and 121 are recognized by antibodies) was 
selectively observed in the supernatants of DCs obtained by in vitro DCs maturation 
in presence of PGE2. Conversely VEGF was not produced by immature DCs or by 
DCs activated at the presence of Poly I:C and lower production was observed in DCs 
matured with the PGE2-depleted cocktail. 
 
Because it has been reported that in DCs, IL-10 and PGE2 treatments up-regulate 
the production of Thrombospondin 1, an anti-angiogenic molecule (Doyen V., et al., 
2003), we next investigate (ELISA assay) the pro and anti-angiogenic properties of 
classic cocktail matured DCs by measuring the levels of Thrombospondin 1 and 
Epathocyte Growth Factor (HGF) o Scatter Factor (SF), another pro-angiogenic 
molecule, in supernatants of mDCs.  
 
As shown in table 2, neither iDCs (data not shown) nor mDCs produced detectable 
amount of HGF and Thrombospondin 1.  
Thus, PGE2 treatment of DCs seems to favour a proangiogenic phenotype. 
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4.1.4 DCs CYTOKINES PRODUCTION 
As a consequence of maturation process, MoDCs usually secrete inflammatory 
cytokines (Sallusto F., et al., 1999). To measure this production, we analyzed, by 
qualitative (data not shown) and quantitative RT-PCR, IL-12 p40, IL-12 p35 and IL-23 
p19 mRNA levels; then we set out to investigate, by ELISA assay, the amount of IL-
10, IL-12 and IL-23 present in the cell culture supernatants of immature MoDCs and 
after 48 hours of stimulation with the standard cocktail or with TNF-α, IL-1β, IL-6 + 
Poly I:C. The mRNA and cytokines production is reported in tables 3 and 4. 
 
IL-10 
According to previous reports, IL-10 production was low in Poly I:C matured DCs 
(data not shown), while it was significantly increased in immature DCs treated with 
TNF-α, IL-1β, IL-6 + PGE2 cocktail (table 4). 
 
IL-12  
Because VEGF and IL-10 are reported to inhibit IL-12 production and Th1 
differentiation by activated DCs, we evaluated the ability of DCs matured with the 
standard cocktail to modulate IL-12 p35 and IL-12 p40 gene expression by Real Time 
RT-PCR and to produce IL-12 protein by ELISA test.  
It is noteworthy that DCs matured with PGE2 were inhibited in their ability to produce 
IL-12p70 (table 4), a cytokine with potent antiangiogenic and Th1-driving activity 
(Penna G., et al., 2000; Takahashi A., et al., 2004).  
 
Although PGE2-treated DCs were strongly induced to produce IL-12 p40 mRNA and 
protein, neither p35 gene expression nor the production of bioactive IL-12p70 
heterodimer were observed under these conditions (tables 3 and 4). Moreover, 
maturation induced by PGE2-depleted cocktail or by Poly I:C lead to a smaller 
expression of p40 and a basal expression of p35 (data not shown). 
 
IL-23  
Since IL-23 is predominantly expressed by activated dendritic cells and phagocytic 
cells, and since we observed that PGE2-treated DCs strongly induced the production 
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of IL-12 p40 protein and mRNA, we evaluated the ability of DCs matured with the 
standard cocktail to produce IL-23. 
We observed that PGE2-treated DCs were strongly induced to produce IL-23p19 
mRNA and IL-23 protein (tables 3 and 4). 
Conversely, 23p19 mRNA and IL-23 protein were not produced by immature DCs 
(table 4) or by DCs activated in presence of Poly I:C (data not shown). 
 
 
4.1.5 TEM8 GENE EXPRESSION IN Mo-DCs  
Successively, we set out to investigate the TEM8 and CMG2 gene expression 
profiles of migratory monocyte-derived dendritic cells (matured with soluble 
mediators of the chronic inflammation) versus non migratory MoDCs. 
 
Conventional RT-PCR analysis (figure 5) shows that while CMG2 gene was widely 
expressed both in immature DCs and in PGE2 matured DCs, TEM8 gene expression 
was absent in iDCs, but detectable in PGE2 -matured DCs from some patients. 
 
Relative quantifications in the steady-state expression of the genes by Quantitative 
Real Time-PCR (Q-RT-PCR) confirmed that both monocytes precursors and 
immature DCs accumulate a far larger amount of CMG2 transcripts than TEM8 (table 
5, lanes 1 and 2), while no significant variations of the transcriptional activity for 
TEM8 was observed in the transition from monocytes to immature DCs (figure 6, 
n°1). 
 
However, PGE2-treated DCs selectively enhanced (>15 fold) TEM8 expression (table 
5, lane 3 and figure 6, n° 2) and not CMG2 expression (figure 6, n°3).  
On the other hand, Poly I:C maturation did not change TEM8 gene expression and 
induced CMG2 transcription (figure 6, n°4 and table 5, lanes 4).  
The present finding suggests that TEM8 transcription is strictly PGE2 dependent. 
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4.2 HUMAN BREAST CANCER CELL LINES 
 
 
4.2.1 MIGRATORY PHENOTYPE  
Is widely known that tumor cells express a distinct, not-random pattern of functionally 
active chemokine receptors. Signalling through the chemokine receptors (i.e. CXCR4 
or CCR7) has been reported to mediate actin polymerization and pseudopodia 
formation (protoplasmic extensions involved in the amoeba-like movements of 
migrating cells) in breast cancer cells inducing chemotactic and invasive responses 
(Muller A., et al, 2001; Wang J.M., et al, 1998). 
 
Here we investigated the expression of chemokine receptors CXCR4 and CCR7 in 
the following human breast cancer cell lines: MDA-MB231 and Zr75-1.  
 
Human breast cancer cell lines were maintained in culture as previously described; 
cells were trypsinized, washed with PBS and incubated with fluorescein 
isothiocyanate (CCR7) or phycoerythrin (CXCR4)-labelled monoclonal antibodies 
(mAbs). The fluorescence was analyzed by a FACS Vantage flow cytometer. 
 
Flow cytometric analyses (table 6) showed, according to Muller et al. (Muller A. et al., 
2001), a strong cell-surface expression of chemokines CXCR4 and CCR7 on MDA-
MB231, while in Zr75-1 cells were undetectable.  
The expression of CXCR4/CCR7 was not assessed in SkBr3 cells. 
 
 
4.2.2 MESENCHIMAL MARKERS 
The transformation of epithelial cells into cells of fibroblastic phenotype, known as 
epithelium-to-mesenchyme transition (EMT), allows cells to dissociate from the 
epithelial tissue from which they originate and to migrate freely.  
Beginning of metastasis involves invasion, which has many phenotypic similarities to 
EMT, including a loss of epithelial morphology (mediated by E-cadherin repression), 
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an increase in cell mobility and the acquisition of mesenchymal characteristics (i.e. 
increase in Vimentin and Tenascin-C expression).  
The coordinated changes in cell morphology, associated with the induction of cell 
motility and the disruption of intercellular junctions, are consequences of a signalling 
cascade leading to changes in gene expression. 
 
We set out to investigate the production of epithelial (E-cadherin) and mesenchymal 
markers (Vimentin and Tenascin-C), to confirm the invasive potential of breast 
cancer cell lines used in experiments. 
 
Mukhopadhyay R. reported that injection of 1x106 cells into the tail vein of nude mice 
produces experimental metastasis (Mukhopadhyay R., et al., 1999).  
According to this report, we found that MDA-MB231 cells expressed high levels of 
Vimentin and Tenascin-C (table 6) showing elongated and fibroblast-like morphology 
(figure 9). 
Such morphological/molecular changes were absent in the other cell lines under 
investigation (table 6). 
  
E-cadherin is important for maintenance of morphology and adhesion in differentiated 
epithelia. In our experiments we found that E-cadherin is absent in metastatic MDA-
MB231 and in SkBr3, while is expressed in not-invasive Zr75-1 (table 6).  
 
 
4.2.3 ANGIOGENIC PHENOTYPE  
Since Yan Wu reported that VEGFR-1 is expressed in a variety of human breast 
tumor cell lines (Wu Y., et al., 2006), we tested the production of VEGF-A in MDA-
MB231, SkBr3 and Zr75-1 cell lines. VEGF-A levels in the cell culture supernatants 
were analyzed using Endogen Human VEGF Elisa Kit (Pierce Biotechnology).  
 
Table 6 shows that the production of VEGF-A was observed at high levels in 
supernatants of MDA-MB231 maintained in culture, while a lower production was 
observed in supernatants of SkBr3 and Zr75-1.  
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4.2.4 PGE2 PRODUCTION 
It is known that PGE2 suppresses antitumor functions of natural killer cells and 
macrophages (Lala P.K. and Saarloos, 1994) and the ability of T lymphocytes to 
produce antitumor Th1 cytokines (TNF-α, IFN-γ and IL-2) (Harris S.G., et al., 2002). 
Tumor-derived PGE2 can directly stimulate tumor growth and metastasis by 
promotion of tumor cell migration, invasiveness and angiogenesis (Rozie J.G., et al., 
2001).  
 
Here we assessed the production of Prostaglandin E2 in highly invasive 
(CXCR4+/CCR7+) MDA-MB231 fibroblastoid breast cancer cells, compared to 
VEGFA-negative, non-invasive ZR75-1 cancer cells.  
The table 6 shows that MDA-MB231 produced higher amounts of PGE2 in the 
surrounding medium than non-invasive cell line Zr75-1. The production of PGE2 was 
not assessed in SkBr3 cells. 
 
 
4.2.5 TEM8 GENE EXPRESSION IN BREAST CANCER CELLS 
Following the intriguing idea that tumor cells might have co-opted some of the 
signaling molecules of innate immune system for invasion and metastases (Muller A., 
et al., 2001), and having showed that TEM8 gene is actively transcribed in migratory 
and pro-angiogenic mDCs, we thought that TEM8 gene could be expressed in 
invasive cancer cells as well.  
We therefore set out to investigate the TEM8 and CMG2 gene expression profiles in 
invasive vs. non-invasive human breast cancer cell lines.  
 
Human breast cancer cell lines were maintained in culture, in growing and starving 
conditions, as previously described (see Material and Methods). After 48h, 
supernatants were harvested and total RNA was extracted. We used 1 µg total RNA 
for synthesis of first-strand complementary DNA (cDNA) by Revert Aid H Minus First 
Strand cDNA Synthesis Kit (Fermentas, Life Sciences).  
The resulting cDNA was used to determine the TEM8 and CMG2 gene expression by 
Qualitative RT-PCR and by Quantitative Real-Time RT-PCR.  
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 Highly invasive (CXCR4+/CCR7+) MDA-MB-231 fibroblastoid breast cancer cells, 
which release potent pro-inflammatory and angiogenic mediators (such as 
Prostaglandin E2 and Vascular Endothelial Growth Factor), constitutively accumulate 
high levels of TEM8 transcripts, as confirmed by Quantitative Real-Time PCR, 
compared to VEGF-negative, PGE2-negative, non invasive ZR75-1 cancer cells 
(figures 7 and 8). 
The figure 8 shows that, by using Zr75-1 as calibrator, TEM8 and CMG2 gene 
expressions were up-regulated in MDA-MB231 cells (> 150 fold and 30 fold 
respectively). On the other hand, TEM8 and CMG2 gene expressions were barely 
detectable in SKBr3 cells.  
 
 
Cocktail treatment of breast cancer cells and TEM8 expression 
Breast cancer cell lines were maintained in culture for 24h as previously described 
(see Material and Methods). Then the cells were stimulated in growing and starving 
conditions with the cytokine cocktail (TNF-α, IL-1β, IL-6 and PGE2).  
Moreover, MDA-MB231, SkBr3 and Zr75-1 cell lines (3x106) were plated (in the 
medium without FBS) on polylysined coverslip in 100 mm dishes and incubated for 
24 hours. Cell cultures were untreated or treated with cytokine cocktail; after 48h, 
cells were fixed, permeabilized and incubated with fluorescein isothiocyanate (FITC)-
labelled phalloidin to evaluate F-actin polymerization. 
 
MDA-MB231, SkBr3 and ZR75-1 were photographed, unstimulated and after 48h of 
stimulation with the cytokine cocktail, by Nikon Eclipse TS100 microscopy. 
After stimulation with cytokine cocktail, no significant morphological variations were 
observed in treated MDA-MB231 and Zr75-1 in comparison to untreated cells (figures 
9 and 10). However we observed significant morphological changes (structures such 
as lamellipodia, filopodia or pseudopodia) in SKBr3 cells in comparison to untreated 
cells (figure 11). 
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Following the phalloidin incubation, confocal images of MDA-MB231, Zr75-1 and 
SkBr3 were acquired by the confocal laser scan microscopy (BIORAD MRC 600) 
(figures 12 and 13). 
Confocal laser scan images of SkBr3 cell line revealed distinct pseudopodia 
formation and a redistribution of F-actin (a process that is a prerequisite for cell 
motility and migration) towards a leading edge after 48h of stimulation with TNF-α, IL-
1β, IL-6 and PGE2 (figure 13). In untreated cells the actin formed a complex network 
in the cortical regions of the cells; on the other hand, in cytokine cocktail treated cells, 
actin filaments were assembled in bundles, which are supposed to play a mayor role 
in cell motility.  
 
After 48h of stimulation, total RNA from MDA-MB231, Zr75-1 and SkBr3 was 
extracted. We used 1 µg total RNA for synthesis of first-strand complementary DNA 
(cDNA). The resulting cDNA was used to determine the TEM8 and CMG2 gene 
expressions by Quantitative Real-Time RT-PCR.  
 
The figure 14 shows that only cytokine-treated SkBr3 enhanced TEM8 (> 20 fold in 
growing and > 50 fold in starving conditions) and CMG2 (10 fold in growing and 15 
fold in starving) gene expressions while no significant variations of the transcriptional 
activities for both genes were observed in MDA-MB231 and Zr75-1 cell lines. 
 
 
TEM8 expression and weight of cocktail components in SKBr3 cells
Human SkBr3 breast cancer cell line was maintained in culture for 24h as previously 
described (see Material and Methods). Then the cells were stimulated in starving 
conditions with: PGE2-depleted cocktail; PGE2; IL-6; IL-6+IL-1β; IL-6+TNF-α; IL-
1β+TNF-α.  
 
After stimulation with different cytokine cocktails we observed a morphological 
change (structures such as pseudopodia) only in cell lines treated with PGE2-
depleted cocktail, with IL-6 + TNF-α or with IL-6+IL-1β in comparison to untreated 
SkBr3 (figures 15,16 and 17).  
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 After 48h of stimulation, total RNA was extracted. We used 1 µg total RNA for 
synthesis of first-strand complementary DNA (cDNA). The resulting cDNA was used 
to determine the TEM8 and CMG2 gene expressions by Quantitative Real-Time RT-
PCR.  
 
The figure 18 shows that PGE2-depleted cocktail and IL-6+IL-1β -treated SkBr3 cells 
enhanced TEM8 (>50 and >40 fold respectively) and CMG2 (15 fold) gene 
expression to a level comparable with complete cocktail-treated SkBr3 in comparison 
to untreated SkBr3 cells. No significant variations of the transcriptional activities for 
both genes were observed in PGE2-, IL-6- and IL-1β+TNF-α- treated SkBr3. 
A lower over-expression of TEM8 and CMG2 genes was observed in IL-6 + TNF-α 
treated SkBr3 (30 and 10 fold respectively) in comparison to untreated SkBr3. 
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5. DISCUSSION 
 
 
 
Recent data expand the concept of a causal relationship between inflammation, 
innate immunity and cancer; however, many of the molecular and cellular 
mechanisms mediating this relationship remain unresolved. Furthermore, tumor cells 
may usurp some of the signalling molecules of the innate immunosystem (i.e. 
adhesion molecules, chemokines ligand and receptors) for invasion migration and 
metastases. 
 
The use of dendritic cells (DCs), which participate to the regulation of the 
inflammatory reaction through the release of specific cytokines and chemokines 
(Banchereau J. et al., 1998), as ‘nature’s adjuvants’ represents a novel approach to 
vaccination against cancer. 
 
Recent technical advances in the culture of large numbers of clinical grade DCs from 
leukapheresis products have opened up the opportunity to test these cells in fairly 
large cancer vaccination trials. Several protocols to obtain clinically applicable DCs 
have been described (Bender A. et al., 1996) which include a variety of maturation 
procedures that influence the phenotype and functional characteristics of these cells 
(Spisek R. et al., 2001).  
 
However, because of the complexity of the DCs system, standardization of DCs 
vaccines needs to be the focus of ongoing research in order to obtain a therapy of 
incontrovertible efficacy. Accordingly, one aim of the present study was to evaluate 
possible links between phenotype and migratory/angiogenic programs in MoDCs 
routinely used as anti-cancer vaccines in clinical trials.  
 
The maturation cocktails TNF-α+IL-1β+IL-6+PGE2 and TNF-α+IL-1β+IL-6+Poly I:C 
were compared, and it was observed that while both maturation cocktails were able 
to increase the fraction of cells expressing the cell-surface major histocompatibility 
complex (MHC) and costimulatory molecules, CCR7 upregulation was only observed 
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after maturation with cocktail containing PGE2, a major inducer of this chemokine 
receptor (Scandella E., et al., 2002). 
The different ability of the two maturation cocktails to induce CCR7 up-regulation 
shows the caveats concerning the choice of appropriate maturation agents for DCs in 
clinical cancer vaccine trials (Mcllroy D., et al., 2003). 
In our system, PGE2-matured DCs (CCR7+) showed a migratory phenotype in 
comparison to immature or Poly I:C-matured DCs. So, the use of PGE2 may 
therefore prove to be important for increasing DCs migratory activity.  
 
However, our results show that PGE2-matured DCs were characterized by the 
production of high levels of VEGF-A, a potent pro-angiogenic cytokine and by 
undetectable production of Thrombospondin 1, an anti-angiogenic molecule. 
 
VEGF-A was reported to inhibit IL-12 production and Th1 differentiation; accordingly, 
these pro-angiogenic DCs were strongly induced to down-regulate the production of 
the Th1-inducing cytokine IL-12p70 (PGE2 induces p40 homodimer and p40 
monomer, IL-12 antagonists) and to enhance the production of IL-10, an inhibitor of 
bioactive IL-12p70, thus leading to a shift of the T-helper cell response toward the 
Th2-type. 
 
Our results about the selective induction by PGE2 of inactive/antagonistic IL-12p40 
subunit argue against the proposed Th1-promoting role for PGE2 at the inflammatory 
sites (Rieser C., et al., 1997). On the contrary, the induction of IL-12p40 by PGE2 is 
likely to contribute to selective suppression of Th1-type responses in chronic 
inflammation, and may play a role in the immune deviation induced by the PGE2-
producing tumors (Strassmann G., et al., 1994; Kambayashi T., 1995; Huang M., et 
al., 1996; Handel-Fernandez M.E., et al., 1997; Huang M., et al., 1998; Stolina M., et 
al., 2000). 
 
Recently, an additional heterodimeric cytokine was discovered with many similarities 
to IL-12; this new cytokine, named IL-23, comprises of a p19 subunit that associates 
with the IL-12p40 subunit (Oppmann B., et al., 2000).  
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IL-23 emerged as one of the most potent pro-inflammatory cytokines. IL-23, not IL-
12, functions as the essential factor in some types of chronic inflammation (Cua D.J., 
et al., 2003; Murphy C.A., et al., 2003). 
Our results show that the PGE2-containing cocktail leads to an over-expression of IL-
23p19 mRNA and IL-23 protein production. 
 
IL-23 drives a pathway that leads to the generation of IL-17-producing CD4+ T cells 
(Harrington L.E. et al., 2005; Aggarwal S., et al., 2003; Cua D.J., et al., 2003). The 
induction of IL-23-derived processes leads to recruitment of a range of inflammatory 
cells as well as ThIL-17 T cells, and has been shown to be crucial to the 
pathogenesis of a number of immune-mediated inflammatory diseases (Langrish C., 
et al., 2005).  
IL-23-induced inflammatory processes, such as induction of angiogenesis or 
macrophage and neutrophil infiltration, are valuable defence mechanisms against 
bacterial infections. However, this regulatory pathway appears to be inappropriate for 
eliminating tumors, instead it could provide a protective, tumor-promoting 
environment for nascent malignancies, suggesting that anti-IL-23p19 therapy may 
prove efficacious for tumor treatment (Langowski J. et al., 2006). 
 
In our experiments we clearly show that the standard cytokine cocktail used in clinical 
trials (TNF-α, IL-1β, IL-6 + PGE2) might induce an unfavourable cytokine profile when 
used as DCs maturation cocktail since DCs obtained show a pro-angiogenic and 
Th2-driving phenotype. 
 
Deregulated VEGF expression has been implicated in the development of solid 
tumors by supporting tumor angiogenesis (Ferrara N. et al., 2003). Our results show 
a potential influence of Mo-DCs on tumor angiogenesis.  
 
The resolution of an inflammatory process is characterized by the presence of anti-
inflammatory signals that induce an “alternative/type 2” state of activation of 
infiltrating leukocytes (Goerdt S. and Orfanos C.E., 1999). 
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Signals associated with a type 2-polarized immune response are known to be 
responsible for the inhibition of inflammatory cytokines, the promotion of tissue 
remodelling and repair, the inhibition of Th1 responses. However, type 2-polarizing 
signals are also produced in pathological conditions, including cancer associated to 
chronic inflammation (Yamamura M., et al., 1993). 
Induction of anticancer humoral immune responses might contributes to chronic 
inflammation and enhance neoplastic programming of tissue rather than eradicating 
it. 
 
Within the pro-angiogenic and migratory programs activated in mDCs, we evaluated 
the expression of tumor endothelial marker 8 (TEM8). 
TEM8 transcripts, found to be up-regulated in angiogenesis, are involved in cell-cell 
communications, adhesion, extracellular matrix remodeling and cellular migration 
rather than in angiogenesis initiation or integrative control.  
Comparison of tissues-specific TEM8 expression patterns shows indeed that the 
presumptive tumor-specific endothelial marker is more generally expressed by cell 
types, like DCs, involved in extra cellular matrix remodeling and migration processes. 
 
Results we obtained show that TEM8 gene is actively and selectively transcribed as 
part of internal pro-angiogenic and migratory programs, switched on in PGE2-
activated MoDCs. 
 
Evidence suggests that mechanisms used for homing of leukocytes may be 
appropriated for the dissemination of tumours via the bloodstream and lymphatic 
(Muller A., et al., 2001). 
Having showed that TEM8 gene is up-regulated in migratory and pro-angiogenic 
mDCs we thought that this gene could be actively transcribed in invasive cancer cells 
as well. 
We therefore set out to investigate TEM8 and CMG2 gene expression profiles in 
invasive versus non-invasive human breast cancer cell lines.  
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Breast cancer is characterized by a distinct metastatic pattern involving the regional 
lymph nodes, bone marrow, lung and liver. Although a number of molecules have 
been implicated in the metastasis of breast cancer, the precise mechanisms 
determining the directional migration and invasion of tumor cells into specific organs 
remain to be established (Nicolson G.L., 1993; Wang J.M., et al., 1998; Yeatman 
T.J., 1993). 
 
In the experiments we used three breast cancer cell lines: MDA-MB231 cells with a 
highly invasive phenotype (Thompson E.W., et al., 1992) and with the ability to 
produce experimental metastasis (Mukhopadhyay R., et al., 1999), Zr75-1 cells 
which show a non-invasive, non-metastatic phenotype (Thompson E.W., et al., 1992) 
and finally SkBr3 cells which possess low chemoinvasion and chemotaxis activity. 
We investigated the production of indicators of epithelial-mesenchymal transition (E-
cadherin, Vimentin and Tenascin-C), the chemokines expression and the angiogenic 
potential of cell lines used in experiments to confirm their invasive potential. 
 
Initiation of metastasis involves invasion, which has many phenotypic similarities to 
epithelial-mesenchymal transition (EMT). Epithelial-mesenchymal transition is 
characterized by loss of cell adhesion and epithelial morphology, repression of E-
cadherin expression, increased cell mobility and expression of mesenchymal 
markers. 
 
Carcinoma cells with a well-differentiated epithelial morphology do not invade a 
collagen matrix and produce E-cadherin, an epithelial marker important for 
maintenance of morphology and adhesion in differentiated epithelia. 
In human carcinoma, the loss of epithelial morphology is an important prognostic 
marker and correlates with a poor outcome of the disease.  
 
Our results show that invasive MDA-MB231 expressed Vimentin (intermediate 
filament protein of cytoskeleton normally expressed by cells of mesenchymal origin) 
and Tenascin C (typically seen only at sites of epithelial-mesenchymal interaction, 
with an anti-adhesive effect on many cell types), mesenchymal markers that were 
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undetectable in other cell lines. Instead, the epithelial marker E-cadherin was 
detected only in not-invasive Zr75-1 cells. 
 
Liu X.H. and collaborators report that MDA-MB231 cells express high levels of COX-
2, an inducible enzyme that catalyzes the synthesis of PGs (Liu X.H. and Rose D.P., 
1996).  
PGE2 in particular has been shown to suppress antitumor functions of natural killer 
cells and macrophages (Lala P.K. and Saarloos, 1994) and the ability of T 
lymphocytes to produce antitumor Th1 cytokines (TNF-α, IFN-γ and IL-2) (Harris 
S.G., et al., 2002). Tumor-derived PGE2 can directly stimulate tumor growth and 
metastasis by promotion of tumor cell migration, invasiveness and angiogenesis 
(Rozie J.G., et al., 2001). We show that high COX-2 expressing MDA-MB231 cells 
with high metastatic potential produced higher amounts of PGE2 into surrounding 
media than a non-invasive Zr75-1 cell line. 
 
As already described, tumor cells may usurp some of the signalling molecules of the 
innate immunosystem for invasive and migratory activity; in particular, use of 
chemokines-mediated mechanisms has been recently reported. 
In addition, organs representing the main sites of breast cancer metastasis are the 
most abundant sources of ligands for these tumor-associated receptors (Muller A., et 
al., 2001). In particular, it known that there is an over expression of chemokine 
ligands CXCL12 and CCL21 in organs representing the first destinations of breast 
cancer metastasis (Muller A., et al., 2001). According to this report, we show that 
only MDA-MB231 cell line expressed the chemokine receptors CXCR4 and CCR7. 
 
The angiogenic factor VEGF-A promotes tumor angiogenesis primarily through 
activation VEGFR-1 and VEGFR-2 signalling pathways in endothelial cells. 
VEGFR-2 expression is primarily restricted to endothelial cells. In contrast, functional 
VEGFR-1 expression is found in several normal cell types, such as various 
haematopoietic lineages and smooth muscle cells (Lyden D., et al., 2001; Sawano 
A., et al., 2001; Ishida A., et al., 2001) and in certain tumor cells, such as leukaemias, 
melanoma, prostate carcinoma, breast carcinoma (Bellamy W.T., et al., 1999; Price 
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D.J., et al., 2001), raising the hypothesis that angiogenic factors may promote tumor 
growth both by inducing angiogenesis and directly signalling through activation of 
VEGFR-1 on tumor cells. 
In our experiments we obtained that VEGF-A was predominantly expressed in MDA-
MB231, in comparison to Zr75-1 and SkBr3 cells; thus, this cell line represents a 
source of angiogenic stimuli contributing to tumor growth. 
Accordingly, Bachelder reports that VEGF produced by breast carcinoma cells is 
critical for their invasion, and that the chemokine receptor CXCR4, which mediates 
the metastatic process of these cells toward SDF-1, is an important target of this 
autocrine pathway (Bachelder R.E. et al., 2002).  
 
Next, because the results we obtained confirm the constitutive activation of pro-
angiogenic and migratory programs in MDA-MB231 cells, compared to Zr75-1 and 
SkBr3 cells, we quantitate TEM8 gene expression in this different breast cancer cells. 
By doing that, we discovered a selective up-regulation of TEM8 in MDA-MB231 cells 
respect to Zr75-1 and SKBr3 cells. 
Of interest, however, we found that TEM8 gene can be turned on in SkBr3 cells after 
treatment with cytokine cocktail used in DCs maturation. 
 
Werner E. and collaborators showed that TEM8 is a new adhesion molecule that 
mediates cell spreading by coupling extracellular ligands to the actin cytoskeleton. 
According to this report, in our experiments the lighting of TEM8 was strictly 
correlated with morphological changes caused by a redistribution of F-actin. 
 
The data presented in this work show, for the first time, that TEM8 gene is activated 
in different migratory cells of tumor microenvironment (tumor, endothelial and 
inflammatory cells). 
We speculate that anti-TEM8 strategies could provide new therapeutic approaches 
against chronic inflammation and tumor evolution. 
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7. FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. DCs phenotype analysis. 
The table shows the percentage of dendritic cells with a particular surface marker. 3-5x105 immature 
(iDCs), cytokine-cocktail (TNF-α, IL-1β, IL-6, PGE2) or TNF-α, IL-1β, IL-6 + Poly I:C (in red) matured 
(mDCs) dendritic cells from melanoma and renal carcinoma patients were incubated with appropriate 
fluorescein isothiocyanate or phycoerythrin-labelled monoclonal antibodies. iDCs and mDCs 
phenotypes were determined by single or two-color fluorescence analysis by a FACS Vantage flow 
cytometer. 
 
 
 
  
 iDC median value%(range) mDC median value%(range) 
CD1a 27 (4.8-53) 3 (0-14) 10 (1-10)  
CD14 2.6 (0-33) 3 (0-25) 1 (0-47) 
CD80 6 (1-23) 43 (14.2-76) 87 (64-95) 
CD86 29 (5.4-75) 80 (21.56-94) 89 (81-93) 
DR 55 (8.2-76) 70.7 (20.18-92) 93 (78 -99) 
CD83 2.08 (0.1-13) 46 (4.72-80) 75 (6-90) 
CCR7 4 (2-5) 86.5 (48-92) 9 (5-37) 
 mDC 86.5(48-92)% iDC 4(2-5)% 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. DCs migratory phenotype: CCR7 expression (% positive cells). 
FACS analyses of CCR7 expression on human immature and cytokine cocktail matured dendritic 
cells. Poly I:C mDCs show the same quantitative CCR7 staining pattern of iDCs (data not shown). 
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 Figure 2. iDCs versus mDCs 111In-Oxine labelled nodal uptake. 
The figure shows static acquisition images with gamma camera 2, 24, and 48 h, and 2, 24, 48 and 72 
h after inoculation with 111In-Oxine-labelled iDCs and mDCs, respectively. 
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Figure 3. Uptake of DCs in draining lymph nodes. 
The figure shows the uptake of DCs (mDCs and iDCs of a melanoma patient labelled with 111In-
Oxine) in draining lymph nodes. 
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Figure 4. DCs angiogenic phenotype. 
ELISA test (Pierce Biotechnology): median values (pg/ml) of VEGF-A (165 and 121 splicing forms) in 
supernatants of iDCs, DCs matured with the standard cocktail, with the PGE2-depleted cocktail or with 
TNF-α, IL-1β, IL-6 and Poly I:C.  
 
 
ELISA ASSAY 
 
 mDC 
(IL-6,IL-1β,TNF-α,PGE2) 
VEGF 1000 
h-HGF nd 
Thrombospondin 1 nd 
 
 
Table 2. Cytokines ELISA assay. 
The table shows the median value (pg/ml) of VEGF-A, h-HGF and Thrombospondin 1 in DC culture 
supernatants. 
On day 9, TNF-α, IL-1β, IL-6 + PGE2 treated-DCs culture supernatant were collected and was carried 
out an ELISA test. nd: not detectable (below the sensitivity of the ELISA systems). 
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REAL TIME RT-PCR 
 
 mDC 
(IL-6,IL-1β,TNF-α,PGE2) 
IL-12 p40 130 (22 - 2000) 
IL-12 p35 1,8 (1 - 7,4) 
IL-12 p40/p35 65,9 
IL-23 p19 53,5 (1,4 - 540) 
 
Table 3. Quantitative-RT-PCR. 
The table shows the median value of relative expression of IL-12p40, IL-12p35 and IL-23p19 in TNF-
α, IL-1β, IL-6 + PGE2 treated-DCs versus immature DCs. 
IL-12 p40/p35 represents ratio of p40 gene expression versus p35 gene expression in cytokine 
cocktail-treated DCs. 
 
 
ELISA ASSAY 
 
 
iDC mDC 
(IL-6,IL-1β,TNF-α,PGE2) 
IL-12 p40 44 (9-225) > 1350 
IL-12 p70 nd nd 
IL-10 7,7 (0,3-15) 51,5 (21,5-200) 
IL-23 nd 700 
 
 
Table 4. Cytokines ELISA assay. 
The table shows the median value (pg/ml) of IL-12 p40, IL-12 p70, IL-10 and IL-23 in DCs culture 
supernatants. 
On day 7 (iDCs) and on day 9 (TNF-α, IL-1β, IL-6 + PGE2 treated-DCs) the DCs culture supernatant 
were collected and was carried out an ELISA test to measure the production of the cytokines. nd: not 
detectable (below the sensitivity of the ELISA systems). 
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 Figure 5. RT PCR-Steady State mRNA. 
The figure shows TEM8 and CMG2 gene expression measured by Qualitative RT-PCR in immature 
dendritic cells and dendritic cells matured with the cytokine cocktail (TNF-α, IL-1β, IL-6, PGE2). 
One µl of each reverse-transcription reactions was used to amplify either the extra cellular and 
transmembrane domain of human TEM8 (594 bp fragment) or a portion of the extra cellular domain of 
human capillary morphogenesis protein 2 (200 bp fragment). 
Primers used are described in Material and Methods. 
Numbers indicates DCs from different patients. B: negative control, Mw: molecular weight. 
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CELLS mRNA ratio medium value (range) 
Mos CMG2 vs TEM8 143 
iDCs CMG2 vs TEM8 230 (50-461) 
mDCs CMG2 vs TEM8 150 (60-278) 
mDCs (Poly I:C) CMG2 vs TEM8 487 (350-627) 
 
 
Table 5. Quantitative-RT-PCR.  
The table shows the medium value of ratio of CMG2/TEM8 transcripts in precursor Mos, iDCs, mDCs 
(TNF-α, IL-1β, IL-6 + PGE2) and TNF-α, IL-1β, IL-6 + Poly I:C treated DCs. 
One µl of each reverse-transcription reactions was used to amplify 200 bp in extra cellular domains of 
human TEM8 and CMG2. 
Primers used are described in Material and Methods. 
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Figure 6. Quantitative-RT-PCR.  
Relative expression of TEM8 and CMG2 in precursor Mos, iDCs, mDCs (CTK+PGE2) and mDCs (CTK 
+ Poly I:C). 
One µl of each reverse-transcription reactions was used to amplify 200 bp in extra cellular domains of 
human TEM8 and CMG2. 
Primers used are described in Material and Methods. 
1) TEM8; iDCs vs Mo. 2) TEM8; mDCs (CTK+PGE2) vs iDCs. 3) CMG2; mDCs (CTK+PGE2) vs iDCs. 
4) TEM8; mDCs (CTK+PolyI:C) vs iDCs.  
Calibrators: Mo and iDCs =1. 
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MDA-MB 231 
Highly Invasive 
ZR 75-1 
Not Invasive SkBr3 
Chemokine 
receptors CCR7+/CXCR4+ nd na 
*Vimentin +++ - - 
*Tenascin-C +++ - - 
#E-cadherin - + - 
VEGF-A 
(pg x 106 cells/ml) 10000 900 500 
PGE-2  
(pg/ml) 500 nd na 
 
 
 
Table 6. Breast cancer cells phenotype.  
Chemokine receptors were measured by FACS analyses. *Mesenchymal markers. #Epithelial marker. 
Mesenchymal and epithelial markers were detected by Western Blotting analyses of cellular lysates. 
VEGF-A and PGE2 were measured by ELISA test kit (Pierce Biotechnology and Cayman Chemicals 
Co respectively). 
na: not assessed, nd: not detectable.  
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       B     MW    MB     SK    ZR 
 
 
                                          200bp 
 
 
 
 
 
 
 
Figure 7. Qualitative RT-PCR. 
The figure shows TEM8 gene expression measured by Qualitative RT-PCR (20 cycles) in untreated 
MDA-MB231, SkBr3 and Zr75-1 cell lines cultured in growing conditions.  
One µl of each reverse-transcription reactions was used to amplify a portion of the extra cellular 
domain of human TEM8 (200 bp fragment). Primers used are described in Material and Methods. 
B: negative control, Mw: molecular weight. 
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Figure 8. Quant
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 MDA-MB231 SkBr3 Zr75-itative-RT-PCR.  
2 gene expression in untreated MDA-MB231, SkBr3 and Zr75-1 breast cancer cell 
growing and starving conditions (Zr75-1 calibrator = 1). 
everse-transcription reactions was used to amplify 200 bp in extra cellular domains of 
d CMG2. Primers used are described in Material and Methods. 
69
  
 
MDA-MB231 untreated 
 
 
 
 
MDA-MB231 treated 
 
 
 
Figure 9. MDA-MB231. Images acquired by Nikon Eclipse TS100 microscopy. 
MDA-MB231 cells were stimulated with the cytokine cocktail, in starving conditions. After 48 h, treated 
and untreated cells were photographed by optic microscopy. 
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Zr75-1 untreated 
 
 
 
 
Zr75-1 treated 
 
 
 
Figure 10. Zr75-1. Images acquired by Nikon Eclipse TS100 microscopy. 
Zr75-1 cells were stimulated with the cytokine cocktail, in starving conditions. After 48 h, treated and 
untreated cells were photographed by optic microscopy. 
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SkBr3 untreated 
 
 
 
 
SkBr3 treated 
 
 
 
Figure 11. SkBr3. Images acquired by Nikon Eclipse TS100 microscopy. 
SkBr3 cells were stimulated with the cytokine cocktail, in starving conditions. After 48 h, treated and 
untreated cells were photographed by optic microscopy. 
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Zr75-1 
 
 
 
 
MDA-MB231 
 
 
 
 
MDA-MB231 
 
 
 
Figure 12. Confocal images. 
Images acquired at the confocal laser scan microscopy (BIORAD MRC 600). 
Zr75-1 and MDA-MB231 cells were plated in media without FBS on polylysined cover slip; at 48h, 
cells were fixed, permeabilized and incubated with fluorescein isothiocyanate (FITC)-labelled 
phalloidin. 
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SkBr3 untreated 
 
 
 
 
SkBr3 treated 
 
 
 
 
SkBr3 treated 
 
 
Figure 13. Confocal images. 
Images acquired at the confocal laser scan microscopy (BIORAD MRC 600). 
SkBr3 cells were plated in media without FBS on polylysined cover slip; at 24 h, cells were untreated 
or treated with TNF-α 20ng/ml, IL-1β 20ng/ml, IL-6 2000UI/ml and PGE2 1µg/ml. After 48h, untreated 
and treated cells were fixed, permeabilized and incubated with fluorescein isothiocyanate (FITC)-
labelled phalloidin. 
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Figure 14. Qu
TEM8 and CM
MB231, SkBr3
One µl of each
human TEM8 a
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       MDA-MB231             SkBr3                   Zr75-antitative-RT-PCR.  
G2 gene expressions in growing and starving conditions in cytokine-treated MDA-
 and Zr75-1 breast cancer cell lines (untreated cell lines calibrator = 1) 
 reverse-transcription reactions was used to amplify 200 bp in extra cellular domains of 
nd CMG2. Primers used are described in Material and Methods. 
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SkBr3 treated (TNF-α, IL-1β and IL-6) 
 
 
 
 
SkBr3 treated (PGE2) 
 
 
 
Figure 15. SkBr3. Images acquired by Nikon Eclipse TS100 microscopy. 
SkBr3 cells were stimulated with TNF-α+IL-1β+IL-6 or with PGE2 alone, in starving conditions. After 48 
h, treated cells were photographed by optic microscopy. 
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SkBr3 treated (IL-6) 
 
 
 
 
SkBr3 treated (IL-1β + TNF-α) 
 
 
 
Figure 16. SkBr3. Images acquired by Nikon Eclipse TS100 microscopy. 
SkBr3 were stimulated with IL-6 or with TNF-α+IL-1β, in starving conditions. After 48 h, treated cells 
were photographed by optic microscopy. 
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SkBr3 treated (IL-6+TNF-α) 
 
 
 
 
SkBr3 treated (IL-6+IL-1β) 
 
 
 
Figure 17. SkBr3. Images acquired by Nikon Eclipse TS100 microscopy. 
SkBr3 cells were stimulated with IL-6+TNF-α or with IL-6+IL-1β, in starving conditions. After 48 h, 
treated cells were photographed by optic microscopy. 
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Figure 18. Quantitative-RT-PCR. 
TEM8 and CMG2 gene expression in starving conditions in cytokine-treated (complete cocktail; 
complete cocktail – PGE2; PGE2; IL-6; IL-1β+TNF-α; IL-6+IL-1β; IL-6+TNF-α) SkBr3 cells. 
Untreated SkBr3 calibrator = 1. 
One µl of each reverse-transcription reactions was used to amplify 200 bp in extra cellular domains of 
human TEM8 and CMG2. Primers used are described in Material and Methods. 
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